Use of Anti-Thrombotic Drugs and In-Hospital Mortality in Acute Aortic Dissection Patients
1
Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan
2
Division of Cardiovascular Surgery, Department of Surgery, Kurume University School of Medicine, Kurume 830-0011, Japan
*
Author to whom correspondence should be addressed.
Diagnostics 2022, 12(10), 2322; https://doi.org/10.3390/diagnostics12102322
Submission received: 23 August 2022
/
Revised: 19 September 2022
/
Accepted: 20 September 2022
/
Published: 26 September 2022
(This article belongs to the Special Issue Thoracic Aortic Disease: From Bench to Bedside)
Abstract
:Acute aortic dissection occurs due to a primary tear in the aortic intima, with blood from the aortic lumen entering the adjacent diseased media. In the clinical setting, practitioners often hesitate before the use of anti-thrombotic drugs in the acute phase of aortic dissection. Therefore, we examined the clinical course in patients who had already received antithrombotic therapies at the onset of acute aortic dissection, and who were given anti-thrombotic drugs in the acute phase during hospitalization. We retrospectively enrolled 685 consecutive patients with acute aortic dissection (type A/B: 454/231), who were transferred to Kurume University Hospital from 2004 to 2020. In types A and B, there were no significant differences between in-hospital mortality with or without antithrombotic therapies at the onset (14.3% vs. 16.4%, p = 0.66 in type A, 2.6% vs. 7.3%, p = 0.29 in type B). Patients in type A who survived more than a day and were treated with anti-thrombotic drugs during hospitalization had significantly lower in-hospital mortality compared with those who received no anti-thrombotic drugs in the acute phase (2.2% vs. 16.1%, p < 0.001), while there was no significant difference between in-hospital mortality in the two type-B groups (2.4% vs. 4.9%, p = 0.48). Although there were variations in response among patients with acute aortic dissection, anti-thrombotic drugs did not worsen in-hospital mortality for patients with acute aortic dissection, indicating that medical staff should not hesitate to administer anti-thrombotic drugs if indicated.
1. Introduction
Acute aortic dissection has poor prognosis, [1,2] frequently resulting in sudden cardiac death. There are several classifications of acute aortic dissection, among which Stanford type A is classified as “all dissections involving the ascending aorta, regardless of the site of origin”, and Stanford type B as “all dissections not involving the ascending aorta” [3]. Historically, the mortality of Stanford type A has approached 1% per hour [4] while Stanford type B has shown 10 to 25% mortality at 30 days [3]. Although diagnostic modalities and therapeutic strategies including surgical and endovascular treatment have recently advanced, mortality rates remain high [5].
Accumulated evidence has demonstrated that inflammation plays a central role in the pathogenesis of acute aortic dissection [6,7,8]. Acute aortic dissection occurs due to a primary tear in the aortic intima, with blood from the aortic lumen penetrating into diseased media [8], and thrombus often occurs in the false lumen. It has been reported that the false lumen status is associated with poor outcomes [9]. Meta-analysis has indicated that partial thrombosis in the false lumen is independently associated with poor long-term survival after acute aortic dissection, compared with complete thrombosis or patent false lumen [9]. Although the underlying mechanisms involved in the association between outcomes and false lumen status have not been fully elucidated, complete thrombus formation in the false lumen has been considered a prerequisite for healing the aorta [9]. In addition, complete thrombus may be able to relieve pressure from the tear; however, it may conversely cause organ ischemia. Furthermore, in cases of partial thrombosis in the false lumen, thrombus and platelets can modulate inflammatory reactions and immune responses [10,11]. It remains unknown how anti-thrombotic drugs affect thrombus formation in the false lumen.
Data remain scant regarding anti-thrombotic therapies in such situations, and practitioners in the clinical setting often hesitate to apply anti-thrombotic drugs in the acute phase of aortic dissection. However, anti-thrombotic drugs are occasionally required during hospitalization after acute aortic dissection, for various reasons including atrial fibrillation. Furthermore, acute aortic dissection can occur suddenly even in patients who already receive daily anti-thrombotic therapies.
Although several case reports have focused on anti-thrombotic therapy in aortic dissection [12], it is unknown whether patients with acute aortic dissection who have taken anti-thrombotic drugs have worse or comparable prognoses compared with those who have not received such treatment. Therefore, the present study aimed to examine in-hospital mortality in patients with acute aortic dissection, who were already being treated with anti-thrombotic therapies at the onset, and who were treated with anti-thrombotic agents during hospitalization in the acute phase.
2. Materials and Methods
2.1. Study Design
This study was a retrospective observational study using the database of the Coronary Care Unit/Cardiovascular Medicine, Kurume University Hospital. We enrolled patients with acute aortic dissection who were transferred to Coronary Care Unit/Cardiovascular Medicine, Kurume University Hospital, from January 2004 to December 2020. We defined “transferred“ patients as all patients who were transferred to our hospital, and “hospitalized“ as those who survived for more than a day while in our hospital. The present study was approved by the institutional review board at Kurume University (21280). Informed consent was waived due to the retrospective nature of the study.
2.2. Data Collection
Baseline demographic data were collected when patients arrived at the hospital, based on their medical records, including age, sex, height, body weight, waist measurement, medications including anti-thrombotic drugs (warfarin, direct oral anti-coagulants (DOAC), aspirin, clopidogrel), traditional risk factors (hypertension, glucose intolerance, diabetes mellitus, and dyslipidemia), blood pressure (BP), pulse rate, heart rate, and comorbidities (coronary artery disease, hypertensive heart disease, cardiomyopathy, valvular heart diseases, and congenital heart diseases). We recorded whether patients had already received anti-thrombotic drugs at the time of transferal, and whether those drugs were administered during hospitalization. Consciousness at arrival was evaluated using the Japan Coma Scale (JCS), which is the most commonly applied method for assessing patients’ consciousness levels: 0, alert consciousness; 1–3 (single digit), awake without any stimuli; 10–30 (double digits), arousable by some stimuli but reverting to previous state if stimulus stops; and 100–300 (triple digits), unarousable by any stimuli [13]. Coronary artery diseases included chronic stable angina, asymptomatic myocardial ischemia, acute coronary syndrome, prior myocardial infarction, prior coronary revascularization, coronary spastic angina, and nonobstructive coronary atherosclerosis. Venous thromboembolism included pulmonary thromboembolism and deep vein thrombosis. Left ventricular (LV) dysfunction was defined as LV ejection fraction <50%. The disease category “genetic and others” included Marfan syndrome, Loeys–Dietz syndrome, and Behçet’s disease. Other clinical diagnoses and medication data were obtained from medical records. All patients had their smoking and drinking habits ascertained by a questionnaire. Alcohol intake and smoking were classified as current habitual use or not. Major bleeding was defined as fatal bleeding and/or symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular, pericardial, or intramuscular with compartment syndrome, referring to the International Society on Thrombosis and Haemostasis [14]. Infarction included myocardial, cerebral, and peripheral, including arterial infarction of the abdomen or limbs. Myocardial infarction was diagnosed by electrocardiography (ECG) and echocardiography. Cerebral and peripheral arterial infarctions, including abdominal and limb, were diagnosed by imaging, including computed tomography scan. Details of paroxysmal atrial fibrillation were collected from medical records, having been diagnosed by ECG monitor or 12-lead ECG. Data of deaths during hospitalization were collected from medical records. All cardiovascular diseases were diagnosed by expert cardiologists.
2.3. Blood Sampling
Blood samples were obtained from the antecubital vein and measured at a commercial laboratory in Kurume University Hospital. Estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease (MDRD) study equation modified with a Japanese coefficient [15]: eGFR (ml·min–1·1.73 m−2) = 194 × age−0.287 × serum creatinine−1.094 (if female × 0.739).
2.4. Outcome
Primary outcome was defined as death from any cause during hospitalization, and secondary outcomes were defined as “major bleeding”, “infarction by aortic dissection”, and “paroxysmal atrial fibrillation”, all of which were identified in the medical records.
2.5. Statistical Analysis
Data were presented as mean ± standard error (SE) and compared between groups using two-sided t-tests. Categorical variables were presented as frequency and percent proportions and were compared between groups using chi-square tests. Survival curves for deaths from all causes were estimated by the Kaplan–Meier method and compared using the log-rank test. Cox proportional hazards models were applied to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for all-cause mortality. Next, we adjusted the models for age and sex. Surgical procedure and traditional cardiovascular risk factors were considered as covariates. Statistical significance was defined as p < 0.05. All statistical analyses were performed using the SAS system (Release 9.4, SAS Institute, Cary, NC, USA).
3. Results
3.1. Transferred Patients
3.1.1. Prognosis in Transferred Patients
A total of 685 patients with acute aortic dissection were transferred to our hospital from January 2004 to December 2020 (Figure 1). There were 454 type-A and 231 type-B patients. From type A, 70 patients were treated by anti-thrombotic drugs on admission, including 24 with anti-coagulants, 39 with anti-platelet drugs, and seven with both (Figure 1). Baseline characteristics of transferred patients, including their use of anti-thrombotic drugs divided into anti-coagulants and anti-platelets, are shown in Table 1, Table 2 and Table 3.
Among 685 transferred patients, 15% of 454 type-A and 16% of 231 type-B patients had already taken anti-thrombotic drugs.
Type-A patients who were already being treated by anti-thrombotic drugs were significantly older, and showed a higher prevalence of previous history of atrial fibrillation, cardiovascular disease, coronary artery bypass graft, and aortic valve replacement, as well as increased use of renin-angiotensin-aldosterone system (RAAS) inhibitors (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers), calcium channel blockers, and β-blockers. Among them, 10 patients (14.3%) died during hospitalization (Figure 1). Of the remaining 384 patients with type-A acute aortic dissection who were not treated with anti-thrombotic drugs, 63 (16.4%) died during hospitalization (Figure 1). As indicated by the Kaplan–Meier curve, patients in type A who were treated with anti-thrombotic drugs on admission did not show worse prognosis compared with the group receiving no anti-thrombotic drugs (Figure 2A).
Furthermore, we separately analyzed the prognosis of patients receiving anti-thrombotic drugs in the categories “anti-coagulants”, “anti-platelet drugs”, and “both of them” (Figure 3). There were no significant differences in survival rates among groups receiving different anti-thrombotic drugs on admission in either type A (Figure 3A) or type B (Figure 3B).
In type B, 38 patients were treated by anti-thrombotic drugs on admission, including 11 with anti-coagulants, 22 with anti-platelet drugs, and 5 with both. This group had significantly higher prevalence of previous history of atrial fibrillation, coronary artery disease, dyslipidemia, aortic valve replacement, and coronary artery bypass graft, as well as RAAS inhibitor use (Figure 1, Table 1, Table 2 and Table 3). Among them, one patient (2.6%) died during hospitalization. Of the remaining 193 patients with type B who were not treated with anti-thrombotic drugs, 14 patients (7.3%) died during hospitalization. The Kaplan–Meier curve reveals the comparable prognosis between the two type-B groups (Figure 2B).
3.1.2. Cox Proportional Hazards Regression Analysis of All-Cause Death in Transferred Patients in Type A
The Cox proportional hazards regression analysis indicated that systolic blood pressure, eGFR, history of hypertension, smoking habit, alcohol intake, complications of surgical procedures, and use of α-blockers were significantly associated with death from all causes (Table 4). According to this analysis, the use of anti-thrombotic drugs (warfarin, DOAC, aspirin, clopidogrel) was not a predictor of all cause death (Table 4).
Systolic blood pressure, eGFR, history of hypertension, smoking habit, alcohol intake, complications of surgical procedures, and use of α-blockers were significantly associated with death from all causes, after adjustment for age and sex (Table 3, Supplementary Table S1). Furthermore, the use of anti-thrombotic drugs (warfarin, DOAC, aspirin, clopidogrel) was not a predictor of all-cause death (Table 5, Supplementary Table S1), and this finding remained consistent in the fully adjusted models (Supplementary Table S1).
3.1.3. Cox Proportional Hazards Regression Analysis of All-Cause Death in Transferred Patients in Type B
In the Cox proportional hazards regression analysis of all-cause death, systolic blood pressure, heart rate, eGFR, history of atrial fibrillation, complications of surgical procedures, and use of diuretics were significantly associated with death from all causes (Table 4). It was also revealed in in this analysis that the use of anti-thrombotic drugs (warfarin, DOAC, aspirin, clopidogrel) was not a predictor of all-cause death (Table 4).
After adjustment for age and sex, systolic blood pressure, heart rate, eGFR, history of atrial fibrillation, complications of surgical procedures, and use of diuretics were significantly associated with death from all causes (Table 5, Supplementary Table S2), while the use of anti-thrombotic drugs was not a predictor of all-cause death, even when the association was adjusted for other confounders (Table 5, Supplementary Table S2).
3.2. Hospitalized Patients
3.2.1. Prognosis in Hospitalized Patients
A total of 650 patients with acute aortic dissection survived for more than a day when hospitalized (Figure 4). This figure included 424 type-A and 226 type-B patients. In type A, 182 patients were treated by anti-thrombotic drugs during hospitalization, including 64 with anti-coagulants, 73 with anti-platelet drugs, and 45 with both. Baseline characteristics of hospitalized patients, including their anti-thrombotic drug treatment by anti-coagulants or anti-platelet agents, are shown in Table 6, Table 7 and Table 8. Type-A patients had a significantly higher prevalence of atrial fibrillation in association with anti-coagulant therapy, and genetic and other aortic diseases including Marfan syndrome, Loeys-Dietz syndrome, and Behçet’s disease in association with anti-coagulant and anti-platelet therapies (Table 6, Table 7 and Table 8).
Among 650 hospitalized patients, 43% of 424 type-A and 19% of 225 type-B patients were treated with anti-thrombotic drugs during hospitalization.
Among them, four patients (2.2%) died during hospitalization, and 178 (97.8% were discharged (Figure 4). Of the remaining 242 type-A patients who were not treated with anti-thrombotic drugs, 39 (16.1%) died and 203 (83.9%) were discharged (Figure 4). The Kaplan–Meier curve shows the significantly better prognosis in patients in type A treated with anti-thrombotic drugs (Figure 5A).
Survival rate was significantly better in the anti-thrombotic drug group than the other group in type A (Figure 5A), while in type B there was no significant difference between those with and without anti-thrombotic drug treatment during hospitalization (Figure 5B).
Of 226 type-B patients, 42 were treated with anti-thrombotic drugs, including 15 with anti-coagulants, 26 with anti-platelet drugs, and a single patient who received both (Figure 4). Altogether, this group had significantly higher prevalence of atrial fibrillation, coronary artery disease, aortic valve replacement, and coronary artery bypass graft (Table 6, Table 7 and Table 8). Among them, one patient (2.4%) died, and the remainder were discharged. Among the 184 type-B patients who were not treated by anti-thrombotic drugs, nine of them (4.9%) died during hospitalization (Figure 4). As indicated in the Kaplan–Meier curve, there were no significant differences in prognosis among patients in type B (Figure 5B).
Again, we separately analyzed the prognosis of patients receiving treatment with anti-thrombotic drugs, according to whether they received “anti-coagulants”, “anti-platelet drugs”, or “both of them” (Figure 6). There were no significant differences in survival rates among these groups in either type A (Figure 6A) or type B (Figure 6B).
In Figure 6B, a third survival curve was not obtained because the group receiving “both” treatments contained only one patient, who survived for the whole observational period.
3.2.2. Cox Proportional Hazards Regression Analysis of All-Cause Death in Hospitalized Patients in Type A
In the analysis of deaths from all causes, systolic blood pressure, eGFR, complications of surgical procedures, and use of α-blockers and anti-thrombotic drugs were significantly associated with all-cause death (Table 9). The use of anti-thrombotic drugs (warfarin, DOAC, aspirin, clopidogrel) significantly reduced the hazard ratio (Table 9).
Systolic blood pressure, eGFR, complications of surgical procedures, and use of α-blockers were significantly associated with all-cause death, after adjustment for age and sex (Table 10, Supplementary Table S3). According to this analysis and the fully adjusted models, the use of anti-thrombotic drugs was also a significant and strong predictor of reduced frequency of deaths from all causes (Table 10, Supplementary Table S3).
3.2.3. Cox Proportional Hazards Regression Analysis of All-Cause Death in Hospitalized Patients in Type B
In the analysis of deaths from all causes, it was found that heart rate, history of atrial fibrillation, and complications of surgical procedures were significantly associated with all-cause death (Table 9). In this analysis, the use of anti-thrombotic drugs was not found to be a predictor of all-cause death (Table 9).
History of atrial fibrillation and complications of surgical procedures were significantly associated with all-cause death, after adjustment for age and sex (Table 10, Supplementary Table S4). The use of anti-thrombotic drugs was not a predictor of all-cause death, regardless of cardiovascular risk factors or other confounders (Table 10, Supplementary Table S4).
3.2.4. Analyses of Newly Administered Anti-Thrombotic Agents during Hospitalization
Anti-coagulants were newly administered in 92 patients, while 33 patients had already taken anti-coagulants before admission and continued to do so during hospitalization. Anti-platelet agents were newly administered in 104 patients, while 41 patients had already taken anti-platelet drugs before admission and continued to do so during hospitalization (Table 11). In type A, newly administered anti-thrombotic agents corresponded with significantly better survival rates (Table 11 and Supplementary Table S5).
4. Discussion
This is the first report to demonstrate that the use of anti-thrombotic drugs did not worsen prognosis in patients with acute aortic dissection, although there was considerable heterogeneity between the two groups with and without anti-thrombotic drugs. In the anti-thrombotic drug group, higher prevalence of previous history of atrial fibrillation and cardiovascular disease was observed, which might have worsened prognosis. Although certain hidden conditions might have affected the findings, the use of anti-thrombotic drugs during hospitalization showed significantly better prognosis in type A, where it was observed even after adjustment for age and sex. Probably because more attention was paid to surgical repair in patients who received anti-thrombotic drugs, those drugs did not worsen the prognosis in acute aortic dissection. In particular, type A is difficult for cardiac surgeons to treat with surgical procedures. However, due to the efforts of cardiac surgeons, the use of anti-platelet drugs or anti-coagulants did not worsen prognosis after surgery in type A.
4.1. Initial Medical Therapy in Acute Aortic Dissection
Initial medical therapy should stabilize patients, control pain, and lower blood pressure, to prevent further propagation of the dissection and to reduce the risk of aortic rupture [16]. The present study demonstrated that anti-thrombotic drugs do not worsen the prognosis; however, the new introduction of anti-thrombotic drugs is not recommended before appropriate surgical consultation or transfer of patients to comprehensive aortic centers [16].
4.2. Medical Management during Hospitalization
Blood pressure management is vital for patients with acute aortic dissection [16]. β-adrenergic blockade reduces heart rate and blood pressure, and provides anti-impulse therapy to decrease aortic wall stress [17]. In addition to appropriate blood pressure management, other therapeutic medical strategies are required. Although the present study has demonstrated that prognosis was comparable between patient groups with and without anti-thrombotic drugs during hospitalization with type-B aortic dissection, the anti-thrombotic drug group showed significantly better prognosis among patients with type-A aortic dissection. Even after separation into groups receiving anti-coagulants or anti-platelet agents, both type-A groups showed significantly better prognosis. However, aortic dissection can vary greatly in its presentation, thus reducing the effectiveness of comparison between the two groups with and without anti-thrombotic drugs. Furthermore, anti-thrombotic drugs might not have been administered in severely ill patients, even when they were indicated, while such drugs may have been given to stable patients. In the present study, we were not able to exclude confounding by indication.
4.3. Long-Term Medical Management
Survival rate has been reported between 52% and 94% at 1 year and between 45% and 88% at 5 years in type A [18], and between 56% and 92 % at 1 year and between 48% and 82% at 5 years in type B [19]. Long-term management of acute aortic dissection should be carried out to prevent late-phase complications, including aneurysmal enlargement and aortic rupture. Poorly controlled hypertension has been reported to increase late morbidity and mortality [20,21]. Thus, it is necessary to control blood pressure, to screen patients and relatives for heritable disorders associated with aortic dissection, to complete serial imaging of the aorta, to encourage lifestyle modifications, and to provide education [18,22].
4.4. Limitations
The present study has several limitations. First, it was an observational retrospective cohort study from a single center. Anti-thrombotic drugs were not administered for aortic dissection, but for other cardiovascular diseases such as coronary artery diseases or atrial fibrillation. Because the preoperative use of a drug reflects the existence of a disease (i.e., DOAC for atrial fibrillation) which might affect the outcome, it is impossible to assess whether effects on outcomes are due to the drug or the disease. This study did not aim to show the superiority of anti-thrombotic drugs in patients with acute aortic dissection. A further limitation was that the enrolled patients were hospitalized in the University Hospital, and that this group of patients might be in more severe condition than others. In addition, this study was not able to include hidden data indicating the severity of acute aortic dissection, except those contained in the obtained medical records, which may affect patients’ prognoses. Furthermore, confounding by indication cannot be excluded when considering the use of anti-thrombotic drugs in hospitalized patients with type-A aortic dissection. The postoperative application of drugs was based on each patient’s condition, therefore generating an intention-to-treat bias. Importantly, no data were available detailing long-term prognosis, and no data were included regarding antagonists for anti-thrombotic drugs. We were not able to collect all data regarding other cardiovascular outcomes during hospitalization, such as visceral ischemia, kidney ischemia, limb ischemia, blood transfusion, and extent of surgical therapy, because some of these data had not been retained over the long period covered by the study. Moreover, blood pressure and heart rate data were collected at the point when patients were transferred, even if they had experienced cardiogenic shock or atrial fibrillation.
5. Conclusions
This study has demonstrated that the use of anti-thrombotic drugs did not worsen in-hospital mortality in patients with acute aortic dissection, suggesting that practitioners should not hesitate to administer anti-thrombotic drugs if indicated.
Supplementary Materials
The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/diagnostics12102322/s1, Supplementary Tables S1–S5: Supplementary Table S1. Cox proportional hazard model for all-cause mortality in TRANSFERRED acute aortic dissection patients (type A). Supplementary Table S2. Cox proportional hazard model for all-cause mortality in TRANSFERRED acute aortic dissection patients (type B). Supplementary Table S3. Cox proportional hazard model for all-cause mortality in HOSPITALIZED acute aortic dissection patients (type A). Supplementary Table S4. Cox proportional hazard model for all-cause mortality in HOSPITALIZED acute aortic dissection patients (type B). Supplementary Table S5. Cox proportional hazard model for all-cause mortality.
Author Contributions
Conceptualization, K.H. and Y.F.; methodology, K.H.; formal analysis, N.M.; investigation, E.T. and Y.F.; data curation, E.T.; writing—original draft preparation, K.H. and N.M.; writing—review and editing, Y.F.; supervision, Y.F.; project administration, Y.F. All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Institutional Review Board Statement
The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board at Kurume University (21280, 28 January 2022).
Informed Consent Statement
Informed consent was waived due to the retrospective nature of this study.
Data Availability Statement
The data presented in this study are available on request from the corresponding author. The data are not publicly available due to privacy restrictions.
Conflicts of Interest
The authors declare no conflict of interest.
References
- Goebel, N.; Nagib, R.; Salehi-Gilani, S.; Ahad, S.; Albert, M.; Ursulescu, A.; Franke, U.F.W. One-stage hybrid aortic repair using the frozen elephant trunk in acute DeBakey type I aortic dissection. J. Thorac. Dis. 2018, 10, 4195–4203. [Google Scholar] [CrossRef] [PubMed]
- Shimamoto, T.; Komiya, T.; Tsuneyoshi, H. Fate of uncomplicated acute type B aortic dissection and impact of concurrent aortic dilatation on remote aortic events. J. Thorac. Cardiovasc. Surg. 2019, 157, 854–863. [Google Scholar] [CrossRef] [PubMed]
- Nienaber, C.A.; Eagle, K.A. Aortic dissection: New frontiers in diagnosis and management: Part I: From etiology to diagnostic strategies. Circulation 2003, 108, 628–635. [Google Scholar] [CrossRef] [PubMed]
- Hirst, A.E., Jr.; Johns, V.J., Jr.; Kime, S.W., Jr. Dissecting aneurysm of the aorta: A review of 505 cases. Medicine 1958, 37, 217–279. [Google Scholar] [CrossRef]
- Fukui, T. Management of acute aortic dissection and thoracic aortic rupture. J. Intensive Care 2018, 6, 15. [Google Scholar] [CrossRef]
- Kimura, T.; Shiraishi, K.; Furusho, A.; Ito, S.; Hirakata, S.; Nishida, N.; Yoshimura, K.; Imanaka-Yoshida, K.; Yoshida, T.; Ikeda, Y.; et al. Tenascin C protects aorta from acute dissection in mice. Sci. Rep. 2014, 4, 4051. [Google Scholar] [CrossRef]
- Tahara, N.; Hirakata, S.; Okabe, K.; Tahara, A.; Honda, A.; Igata, S.; Kaida, H.; Abe, T.; Akashi, H.; Tanaka, H.; et al. FDG-PET/CT images during 5 years before acute aortic dissection. Eur. Heart J. 2016, 37, 1933. [Google Scholar] [CrossRef]
- Ohno-Urabe, S.; Aoki, H.; Nishihara, M.; Furusho, A.; Hirakata, S.; Nishida, N.; Ito, S.; Hayashi, M.; Yasukawa, H.; Imaizumi, T.; et al. Role of Macrophage Socs3 in the Pathogenesis of Aortic Dissection. J. Am. Heart Assoc. 2018, 7, e007389. [Google Scholar] [CrossRef]
- Li, D.; Ye, L.; He, Y.; Cao, X.; Liu, J.; Zhong, W.; Cao, L.; Zeng, R.; Zeng, Z.; Wan, Z.; et al. False Lumen Status in Patients With Acute Aortic Dissection: A Systematic Review and Meta-Analysis. J. Am. Heart Assoc. 2016, 5, e003172. [Google Scholar] [CrossRef]
- Aoki, H.; Majima, R.; Hashimoto, Y.; Hirakata, S.; Ohno-Urabe, S. Ying and Yang of Stat3 in pathogenesis of aortic dissection. J. Cardiol. 2021, 77, 471–474. [Google Scholar] [CrossRef]
- Hamad, M.A.; Krauel, K.; Schanze, N.; Gauchel, N.; Stachon, P.; Nuehrenberg, T.; Zurek, M.; Duerschmied, D. Platelet Subtypes in Inflammatory Settings. Front. Cardiovasc. Med. 2022, 9, 823549. [Google Scholar] [CrossRef]
- Bocchino, P.P.; De Filippo, O.; Piroli, F.; Scacciatella, P.; Imazio, M.; D’Ascenzo, F.; De Ferrari, G.M. Anticoagulant and anti-thrombotic therapy in acute type B aortic dissection: When real-life scenarios face the shadows of the evidence-based medicine. BMC Cardiovasc. Disord. 2020, 20, 29. [Google Scholar] [CrossRef]
- Nakajima, M.; Okada, Y.; Sonoo, T.; Goto, T. Development and validation of a novel method for converting the Japan Coma Scale to Glasgow Coma Scale. J. Epidemiol. 2022, JE20220147. [Google Scholar] [CrossRef]
- Schulman, S.; Kearon, C.; Subcommittee on Control of Anticoagulation of the Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J. Thromb. Haemost. 2005, 3, 692–694. [Google Scholar] [CrossRef]
- Matsuo, S.; Imai, E.; Horio, M.; Yasuda, Y.; Tomita, K.; Nitta, K.; Yamagata, K.; Tomino, Y.; Yokoyama, H.; Hishida, A.; et al. Revised equations for estimated GFR from serum creatinine in Japan. Am. J. Kidney Dis. 2009, 53, 982–992. [Google Scholar] [CrossRef]
- Malaisrie, S.C.; Szeto, W.Y.; Halas, M.; Girardi, L.N.; Coselli, J.S.; Sundt, T.M., 3rd; Chen, E.P.; Fischbein, M.P.; Gleason, T.G.; Okita, Y.; et al. 2021 The American Association for Thoracic Surgery expert consensus document: Surgical treatment of acute type A aortic dissection. J. Thorac. Cardiovasc. Surg. 2021, 162, 735–758.e732. [Google Scholar] [CrossRef]
- Svensson, L.G.; Crawford, E.S. Aortic dissection and aortic aneurysm surgery: Clinical observations, experimental investigations, and statistical analyses. Part I. Curr. Probl. Surg. 1992, 29, 817–911. [Google Scholar]
- Braverman, A.C. Acute aortic dissection: Clinician update. Circulation 2010, 122, 184–188. [Google Scholar] [CrossRef]
- Tsai, T.T.; Fattori, R.; Trimarchi, S.; Isselbacher, E.; Myrmel, T.; Evangelista, A.; Hutchison, S.; Sechtem, U.; Cooper, J.V.; Smith, D.E.; et al. Long-term survival in patients presenting with type B acute aortic dissection: Insights from the International Registry of Acute Aortic Dissection. Circulation 2006, 114, 2226–2231. [Google Scholar] [CrossRef]
- Melby, S.J.; Zierer, A.; Damiano, R.J., Jr.; Moon, M.R. Importance of blood pressure control after repair of acute type a aortic dissection: 25-year follow-up in 252 patients. J. Clin. Hypertens. 2013, 15, 63–68. [Google Scholar] [CrossRef]
- Chan, K.K.; Lai, P.; Wright, J.M. First-line beta-blockers versus other antihypertensive medications for chronic type B aortic dissection. Cochrane Database Syst. Rev. 2014, CD010426. [Google Scholar] [CrossRef]
- Chaddha, A.; Eagle, K.A.; Braverman, A.C.; Kline-Rogers, E.; Hirsch, A.T.; Brook, R.; Jackson, E.A.; Woznicki, E.M.; Housholder-Hughes, S.; Pitler, L.; et al. Exercise and Physical Activity for the Post-Aortic Dissection Patient: The Clinician’s Conundrum. Clin. Cardiol. 2015, 38, 647–651. [Google Scholar] [CrossRef] [Green Version]
Figure 1.
Enrollment of transferred patients with acute aortic dissection.
Figure 2.
Kaplan–Meier curves of transferred patients with acute aortic dissection. There were no significant differences in survival rates between patients with and without anti-thrombotic drugs on admission, in both type A (panel (A)) and type B (panel (B)).
Figure 2.
Kaplan–Meier curves of transferred patients with acute aortic dissection. There were no significant differences in survival rates between patients with and without anti-thrombotic drugs on admission, in both type A (panel (A)) and type B (panel (B)).
Figure 3.
Kaplan–Meier curves of transferred patients receiving “anti-coagulants”, “anti-platelet drugs”, and “both of them”, in type A (panel (A)) and type B (panel (B)).
Figure 3.
Kaplan–Meier curves of transferred patients receiving “anti-coagulants”, “anti-platelet drugs”, and “both of them”, in type A (panel (A)) and type B (panel (B)).
Figure 4.
Enrollment of hospitalized patients with acute aortic dissection.
Figure 5.
Kaplan–Meier curves of hospitalized patients with acute aortic dissection, in type A (panel (A)) and type B (panel (B)).
Figure 5.
Kaplan–Meier curves of hospitalized patients with acute aortic dissection, in type A (panel (A)) and type B (panel (B)).
Figure 6.
Kaplan–Meier curves of transferred patients receiving “anti-coagulants”, “anti-platelet drugs”, and “both of them”, in type A (panel (A)) and type B (panel (B)).
Figure 6.
Kaplan–Meier curves of transferred patients receiving “anti-coagulants”, “anti-platelet drugs”, and “both of them”, in type A (panel (A)) and type B (panel (B)).
Table 1.
Clinical characteristics of TRANSFERRED acute aortic dissection patients with and without anti-thrombotic therapy.
Table 1.
Clinical characteristics of TRANSFERRED acute aortic dissection patients with and without anti-thrombotic therapy.
| Stanford Type A (n = 454) | Stanford Type B (n = 231) | ||||||
|---|---|---|---|---|---|---|---|
| Anti-Thrombotic Therapy | Yes | No | p Value | Yes | No | p Value | |
| (at the Onset) | (n = 70) | (n = 384) | (n = 38) | (n = 193) | |||
| Hospital stay (days) | 38.3 ± 35.6 | 28.9 ± 22.1 | 0.04 | 28.7 ± 28.7 | 26.1 ± 20.5 | 0.59 | |
| Age (years old) | 74.8 ± 8.9 | 68.2 ± 12.2 | <0.01 | 69.8 ± 15.0 | 66.0± 11.8 | 0.14 | |
| Sex (male) | 42 (60.0%) | 183 (47.6%) | 0.06 | 21 (55.3%) | 137 (71.0%) | 0.06 | |
| Surgical/endovascular treatment | 59 (84.3%) | 314 (81.8%) | 0.61 | 3 (7.9%) | 30 (15.5%) | 0.22 | |
| JCS | 0 | 52 (74.3%) | 269 (70.1%) | 0.89 | 37 (97.4%) | 180 (93.3%) | 0.75 |
| 1–3 | 8 (11.4%) | 56 (14.6%) | 1 (2.6%) | 8 (4.2%) | |||
| 10–30 | 5 (7.1%) | 31 (8.1%) | 0 (0.0%) | 3 (1.6%) | |||
| 100–300 | 5 (7.1%) | 28 (7.3%) | 0 (0.0%) | 2 (1.0%) | |||
| Medical history | |||||||
| A Fib | 22 (31.4%) | 13 (3.4%) | <0.01 | 9 (23.7%) | 2 (1.0%) | <0.01 | |
| CAD | 14 (20.0%) | 13 (3.4%) | <0.01 | 8 (21.1%) | 3 (1.6%) | <0.01 | |
| Other CVD | 27 (38.6%) | 36 (9.7%) | <0.01 | 12 (31.6%) | 19 (10.0%) | <0.01 | |
| PAD | 19 (27.1%) | 40 (10.8%) | <0.01 | 14 (36.8%) | 36 (18.7%) | 0.01 | |
| VTE | 1 (1.4%) | 1 (0.3%) | 0.18 | 0 (0.0%) | 0 (0.0%) | ||
| HT | 66 (94.3%) | 320 (86.5%) | 0.07 | 37 (97.4%) | 181 (94.8%) | 0.49 | |
| DM | 7 (10.0%) | 26 (7.1%) | 0.39 | 7 (18.9%) | 24 (12.6%) | 0.3 | |
| DLp | 18 (25.7%) | 78 (21.1%) | 0.4 | 19 (50.0%) | 38 (19.9%) | <0.01 | |
| Genetic and others | 1 (1.4%) | 8 (2.1%) | 0.69 | 4 (10.5%) | 4 (2.1%) | <0.01 | |
| Smoking | 30 (44.8%) | 133 (36.7%) | 0.21 | 20 (54.1%) | 127 (67.2%) | 0.13 | |
| Alcohol | 28 (41.8%) | 109 (30.2%) | 0.06 | 12 (32.4%) | 83 (43.9%) | 0.2 | |
| Surgical history | |||||||
| post-AVR | 6 (8.6%) | 2 (0.5%) | <0.01 | 7 (18.4%) | 0 (0.0%) | <0.01 | |
| post-MVR | 0 (0.0%) | 0 (0.0%) | 1 (2.6%) | 0 (0.0%) | 0.02 | ||
| CABG | 2 (2.9%) | 1 (0.3%) | 0.02 | 2 (5.3%) | 0 (0.0%) | <0.01 | |
| Intervention to aortic aneurysm and/or dissection | 11 (15.7%) | 14 (3.8%) | <0.01 | 15 (39.5%) | 13 (6.8%) | <0.01 | |
| Primary outcome | |||||||
| All-cause death | 10 (14.3%) | 63 (16.4%) | 0.66 | 1 (2.6%) | 14 (7.3%) | 0.29 | |
| Secondary outcomes | |||||||
| Major bleeding | 5 (7.1%) | 25 (7.0%) | 0.96 | 1 (2.6%) | 7 (3.6%) | 0.75 | |
| Infarction by aortic dissection | 18 (25.7%) | 78 (21.7%) | 0.46 | 0 (0%) | 20 (10.4%) | 0.04 | |
| Paroxysmal A Fib | 19 (27.1%) | 93 (25.9%) | 0.83 | 2 (5.3%) | 8 (4.1%) | 0.77 | |
| Medication on admission | |||||||
| RAAS inhibitor | 31(45.6%) | 93 (29.1%) | <0.01 | 22 (57.9%) | 52 (28.1%) | <0.01 | |
| CCB | 29 (42.7%) | 97 (30.3%) | 0.05 | 16 (42.1%) | 51 (27.6%) | 0.08 | |
| β-blocker | 26 (38.2%) | 31 (9.7%) | <0.01 | 12 (31.6%) | 29 (15.7%) | 0.02 | |
| diuretics | 9 (13.2%) | 18 (5.6%) | 0.03 | 2 (5.3%) | 8 (4.3%) | 0.8 | |
| α-blocker | 1 (1.5%) | 9 (2.8%) | 0.53 | 0 (0%) | 7 (3.8%) | 0.22 | |
| warfarin | 25 (35.7%) | 0 (0.0%) | 13 (34.2%) | 0 (0.0%) | |||
| DOAC | 6 (8.6%) | 0 (0.0%) | 3 (7.9%) | 0 (0.0%) | |||
| aspirin | 27 (38.6%) | 0 (0.0%) | 20 (52.6%) | 0 (0.0%) | |||
| clopidogrel | 12 (17.1%) | 0 (0.0%) | 5 (13.2%) | 0 (0.0%) | |||
| cilostazol | 8 (11.4%) | 0 (0.0%) | 4 (10.5%) | 0 (0.0%) | |||
| prasugrel | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |||
| Discharge medicine | |||||||
| RAAS inhibitor | 34 (57.6%) | 199 (64.0%) | 0.35 | 23 (62.2%) | 149 (84.7%) | <0.01 | |
| CCB | 26 (44.1%) | 162 (52.1%) | 0.26 | 28 (75.7%) | 163 (92.6%) | <0.01 | |
| β-blocker | 46 (78.0%) | 248 (79.7%) | 0.76 | 33 (89.2%) | 158 (89.8%) | 0.92 | |
| diuretics | 21 (35.6%) | 103 (33.1%) | 0.71 | 8 (21.6%) | 47 (26.7%) | 0.91 | |
| α-blocker | 2 (3.4%) | 11 (3.5%) | 0.96 | 2 (5.4%) | 14 (8.0%) | 0.59 | |
| warfarin | 17 (28.3%) | 59 (18.9%) | 0.09 | 8 (21.6%) | 2 (1.1%) | <0.01 | |
| DOAC | 6 (10.0%) | 15 (4.8%) | 0.11 | 3 (8.1%) | 2 (1.1%) | 0.01 | |
| aspirin | 24 (40.0%) | 76 (24.3%) | 0.01 | 12 (32.4%) | 8 (4.5%) | <0.01 | |
| clopidogrel | 5 (8.3%) | 6 (1.9%) | <0.01 | 5 (13.5%) | 0 (0.0%) | <0.01 | |
| cilostazol | 5 (8.3%) | 1 (0.3%) | <0.01 | 1 (2.7%) | 0 (0.0%) | 0.03 | |
| prasugrel | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |||
Data are mean ± SE, or mean (%), JCS; Japan Coma Scale, A Fib; atrial fibrillation, CAD; coronary artery diseases, CVD; cardiovascular diseases, PAD; peripheral arterial diseases, VTE; venous thromboembolism, LV; left ventricular, HT; hypertension, DM; diabetes mellitus, DLp: dyslipidemia, AVR; aortic valve replacement, MVR; mitral valve replacement, CABG; coronary artery bypass grafting, RAAS; renin-angiotensin-aldosterone system, CCB; calcium channel blocker, DOAC; direct oral anti-coagulant. Genetic and others includes Marfan syndrome, Loeys-Dietz syndrome, and Behçet’s disease.
Table 2.
Clinical characteristics of TRANSFERRED acute aortic dissection patients with and without anti-coagulant therapy.
Table 2.
Clinical characteristics of TRANSFERRED acute aortic dissection patients with and without anti-coagulant therapy.
| Anti-Coagulant Therapy | Stanford Type A (n = 454) | Stanford Type B (n = 231) | |||||
|---|---|---|---|---|---|---|---|
| Yes | No | p Value | Yes | No | p Value | ||
| (at the Onset) | (n = 31) | (n = 423) | (n = 16) | (n = 215) | |||
| Hospital stay (days) | 39.1 ± 34.2 | 29.7 ± 24.0 | 0.15 | 37.5 ± 37.8 | 25.7 ± 20.3 | 0.23 | |
| Age (years old) | 75.3 ± 8.9 | 68.8 ± 12.1 | <0.01 | 61.8 ± 18.3 | 67.0 ± 11.9 | 0.28 | |
| Sex (male) | 20 (64.5%) | 205 (48.5%) | 0.084 | 8 (50.0%) | 150 (69.8%) | 0.1 | |
| Surgical/endovascular treatment | 28 (90.3%) | 345 (81.6%) | 0.22 | 2 (12.5%) | 31 (14.4%) | 0.83 | |
| JCS | 0 | 25 (80.7%) | 296 (69.9%) | 0.39 | 15 (93.8%) | 202 (94.0%) | 0.89 |
| 1–3 | 4 (12.9%) | 60 (14.2%) | 1 (6.3%) | 8 (3.7%) | |||
| 10–30 | 2 (6.5%) | 34 (8.0%) | 0 (0.0%) | 3 (1.4%) | |||
| 100–300 | 0 (0.0%) | 33 (7.8%) | 0 (0.0%) | 2 (0.9%) | |||
| Medical history | |||||||
| A Fib | 18 (58.1%) | 17 (4.1%) | <0.01 | 8 (50.0%) | 3 (1.4%) | <0.01 | |
| CAD | 3 (9.7%) | 24 (5.8%) | 0.39 | 1 (6.3%) | 10 (4.7%) | 0.78 | |
| Other CVD | 8 (25.8%) | 55 (13.4%) | 0.056 | 3 (18.8%) | 28 (13.2%) | 0.53 | |
| PAD | 4 (12.9%) | 55 (13.4%) | 0.94 | 7 (43.8%) | 43 (20.2%) | 0.03 | |
| VTE | 1 (3.2%) | 1 (0.2%) | 0.017 | 0 (0.0%) | 0 (0.0%) | ||
| HT | 29 (93.6%) | 357 (87.3%) | 0.31 | 15 (93.8%) | 203 (95.3%) | 0.78 | |
| DM | 3 (9.7%) | 30 (7.4%) | 0.64 | 4 (25.0%) | 27 (12.7%) | 0.17 | |
| DLp | 3 (9.7%) | 93 (22.8%) | 0.089 | 6 (37.5%) | 51 (23.9%) | 0.23 | |
| Genetic and others | 0 (0.0%) | 9 (2.2%) | 0.4 | 4 (25.0%) | 4 (1.9%) | <0.01 | |
| Smoking | 14 (45.2%) | 149 (37.4%) | 0.39 | 7 (43.8%) | 140 (66.7%) | 0.06 | |
| Alcohol | 14 (45.2%) | 123 (31.0%) | 0.1 | 4 (25.0%) | 91 (43.3%) | 0.15 | |
| Surgical history | |||||||
| post-AVR | 5 (16.1%) | 3 (0.7%) | <0.01 | 7 (43.8%) | 0 (0.0%) | <0.01 | |
| post-MVR | 0 (0.0%) | 0 (0.0%) | 1 (6.3%) | 0 (0.0%) | <0.01 | ||
| CABG | 0 (0.0%) | 3 (0.7%) | 0.63 | 0 (0.0%) | 2 (0.9%) | 0.7 | |
| Intervention to aortic aneurysm and/or dissection | 3 (9.7%) | 22 (5.4%) | 0.32 | 7 (43.8%) | 21 (9.9%) | <0.01 | |
| Primary outcome | |||||||
| All-cause death | 4 (12.9%) | 69 (16.3%) | 0.62 | 1 (6.3%) | 14 (6.5%) | 0.97 | |
| Secondary outcomes | |||||||
| Major bleeding | 3 (9.7%) | 27 (6.8%) | 0.54 | 1 (6.3%) | 7 (3.3%) | 0.53 | |
| Infarction by aortic dissection | 10 (32.3%) | 86 (21.6%) | 0.17 | 0 (0.0%) | 20 (9.4%) | 0.2 | |
| Paroxysmal A Fib | 7 (22.6%) | 105 (26.4%) | 0.64 | 1 (6.3%) | 9 (4.2%) | 0.7 | |
| Medication on admission | |||||||
| RAAS inhibitor | 15 (50.0%) | 109 (30.5%) | 0.027 | 6 (37.5%) | 68 (32.9%) | 0.7 | |
| CCB | 11 (36.7%) | 115 (32.1%) | 0.61 | 5 (31.3%) | 62 (30.0%) | 0.91 | |
| β-blocker | 15 (50.0%) | 42 (11.7%) | <0.01 | 9 (56.3%) | 32 (15.5%) | <0.01 | |
| diuretics | 6 (20.0%) | 21 (5.9%) | 0.004 | 1 (6.3%) | 9 (4.4%) | 0.72 | |
| α-blocker | 0 (0.0%) | 10 (2.8%) | 0.35 | 0 (0.0%) | 7 (3.4%) | 0.45 | |
| warfarin | 25 (80.7%) | 0 (0.0%) | <0.01 | 13 (81.3%) | 0 (0.0%) | <0.01 | |
| DOAC | 6 (19.4%) | 0 (0.0%) | <0.01 | 3 (18.8%) | 0 (0.0%) | <0.01 | |
| aspirin | 7 (22.6%) | 20 (5.6%) | 0.0003 | 5 (31.3%) | 15 (7.3%) | 0.001 | |
| clopidogrel | 0 (0.0%) | 12 (3.3%) | 0.3 | 0 (0.0%) | 5 (2.4%) | 0.53 | |
| cilostazol | 0 (0.0%) | 8 (2.2%) | 0.4 | 0 (0.0%) | 4 (2.0%) | 0.57 | |
| prasugrel | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |||
| Discharge medicine | |||||||
| RAAS inhibitor | 15 (55.6%) | 218 (63.6%) | 0.41 | 10 (66.7%) | 162 (81.8%) | 0.15 | |
| CCB | 11 (40.7%) | 177 (51.6%) | 0.28 | 12 (80.0%) | 179 (90.4%) | 0.2 | |
| β-blocker | 19 (70.4%) | 275 (80.2%) | 0.22 | 13 (86.7%) | 178 (89.9%) | 0.69 | |
| diuretics | 9 ((33.3%) | 115 (33.5%) | 0.98 | 3 (20.0%) | 52 (26.3%) | 0.59 | |
| α-blocker | 0 (0.0%) | 13 (3.8%) | 0.3 | 0 (0.0%) | 16 (8.1%) | 0.25 | |
| warfarin | 14 (51.9%) | 62 (17.9%) | <0.01 | 8 (53.3%) | 2 (1.0%) | <0.01 | |
| DOAC | 6 (22.2%) | 15 (4.3%) | <0.01 | 3 (20.0%) | 2 (1.0%) | <0.01 | |
| aspirin | 11 (40.7%) | 89 (25.7%) | 0.09 | 2 (13.3%) | 18 (9.1%) | 0.58 | |
| clopidogrel | 0 (0.0%) | 11 (3.2%) | 0.35 | 0 (0.0%) | 5 (2.5%) | 0.53 | |
| cilostazol | 1 (3.7%) | 5 (1.5%) | 0.37 | 0 (0.0%) | 1 (0.5%) | 0.78 | |
| prasugrel | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |||
Data are mean ± SE, or mean (%), JCS; Japan Coma Scale, A Fib; atrial fibrillation, CAD; coronary artery diseases, CVD; cardiovascular diseases, PAD; peripheral arterial diseases, VTE; venous thromboembolism, LV; left ventricular, HT; hypertension, DM; diabetes mellitus, DLp: dyslipidemia, AVR; aortic valve replacement, MVR; mitral valve replacement, CABG; coronary artery bypass grafting, RAAS; renin-angiotensin-aldosterone system, CCB; calcium channel blocker, DOAC; direct oral anti-coagulant. Genetic and others includes Marfan syndrome, Loeys-Dietz syndrome, and Behçet’s disease.
Table 3.
Clinical characteristics of TRANSFERRED acute aortic dissection patients with and without anti-platelet therapy.
Table 3.
Clinical characteristics of TRANSFERRED acute aortic dissection patients with and without anti-platelet therapy.
| Anti-Platelet Therapy | Stanford Type A (n = 454) | Stanford Type B (n = 231) | |||||
|---|---|---|---|---|---|---|---|
| Yes | No | p Value | Yes | No | p Value | ||
| (at the Onset) | (n = 46) | (n = 408) | (n = 27) | (n = 204) | |||
| Hospital stay (days) | 37.2 ± 35.2 | 29.6 ± 23.3 | 0.16 | 22.9 ± 18.2 | 27.0 ± 22.5 | 0.37 | |
| Age (years old) | 74.0 ± 8.5 | 68.7 ± 12.2 | <0.01 | 72.0 ± 14.9 | 65.9 ± 12.0 | 0.02 | |
| Sex (male) | 27 (58.7%) | 198 (48.5%) | 0.19 | 11 (40.7%) | 62 (30.4%) | 0.28 | |
| Surgical/endovascular treatment | 37 (80.4%) | 336 (82.4%) | 0.74 | 1 (3.7%) | 32 (15.7%) | 0.09 | |
| JCS | 0 | 31 (67.4%) | 290 (71.1%) | 0.78 | 27 (100%) | 190 (93.1%) | 0.58 |
| 1–3 | 6 (13.0%) | 58 (14.2%) | 0 (0.0%) | 9 (4.4%) | |||
| 10–30 | 4 (8.7%) | 32 (7.8%) | 0 (0.0%) | 3 (1.5%) | |||
| 100–300 | 5 (10.9%) | 28 (6.9%) | 0 (0.0%) | 2 (1.0%) | |||
| Medical history | |||||||
| A Fib | 4 (8.7%) | 31 (7.8%) | 0.83 | 3 (11.1%) | 8 (4.0%) | 0.1 | |
| CAD | 14 (30.4%) | 13 (3.3%) | <0.01 | 7 (25.9%) | 4 (2.0%) | <0.01 | |
| Other CVD | 23 (50.0%) | 40 (10.1%) | <0.01 | 10 (37.0%) | 21 (10.4%) | <0.01 | |
| PAD | 16 (34.8%) | 43 (10.9%) | <0.01 | 9 (33.3%) | 41 (20.3%) | 0.12 | |
| VTE | 0 (0.0%) | 2 (0.5%) | 0.63 | 0 (0.0%) | 0 (0.0%) | ||
| HT | 44 (95.7%) | 342 (86.8%) | 0.08 | 26 (96.3%) | 192 (95.1%) | 0.78 | |
| DM | 4 (8.7%) | 29 (7.4%) | 0.75 | 3 (11.5%) | 28 (13.9%) | 0.75 | |
| DLp | 16 (34.8%) | 80 (20.4%) | 0.025 | 14 (51.9%) | 43 (21.3%) | <0.01 | |
| Genetic and others | 1 (2.2%) | 8 (2.0%) | 0.95 | 2 (7.4%) | 6 (3.0%) | 0.24 | |
| Smoking | 20 (46.5%) | 143 (37.1%) | 0.23 | 15 (57.7%) | 132 (66.0%) | 0.4 | |
| Alcohol | 17 (39.5%) | 120 (31.2%) | 0.26 | 10 (38.5%) | 85 (42.5%) | 0.69 | |
| Surgical history | |||||||
| post-AVR | 2 (4.4%) | 6 (1.5%) | 0.18 | 3 (11.1%) | 4 (2.0%) | 0.01 | |
| post-MVR | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (0.5%) | 0.71 | ||
| CABG | 2 (4.4%) | 1 (0.3) | 0.001 | 2 (7.4%) | 0 (0.0%) | <0.01 | |
| Intervention to aortic aneurysm and/or dissection | 9 (19.6%) | 16 (4.1%) | <0.01 | 10 (37.0%) | 18 (9.0%) | <0.01 | |
| Primary outcome | |||||||
| All-cause death | 8 (17.4%) | 65 (15.9%) | 0.8 | 0 (0.0%) | 15 (7.4%) | 0.15 | |
| Secondary outcomes | |||||||
| Major bleeding | 3 (6.5%) | 27 (7.1%) | 0.89 | 0 (0.0%) | 8 (4.0%) | 0.29 | |
| Infarction by aortic dissection | 12 (26.1%) | 84 (21.9%) | 0.52 | 0 (0.0%) | 20 (9.9%) | 0.087 | |
| Paroxysmal A Fib | 14 (30.4%) | 98 (25.6%) | 0.48 | 1 (3.7%) | 9 (4.5%) | 0.86 | |
| Medication on admission | |||||||
| RAAS inhibitor | 20 (44.4%) | 104 (30.3%) | 0.056 | 17 (63.0) | 57 (29.1%) | <0.01 | |
| CCB | 20 (44.4%) | 106 (30.9%) | 0.068 | 11 (40.7%) | 56 (28.6%) | 0.2 | |
| β-blocker | 15 (33.3%) | 42 (12.2%) | <0.01 | 5 (18.5%) | 36 (18.4%) | 0.98 | |
| diuretics | 3 (6.7%) | 24 (7.0%) | 0.93 | 1 (3.7%) | 9 (4.6%) | 0.83 | |
| α-blocker | 1 (2.2%) | 9 (2.6%) | 0.87 | 0 (0.0%) | 7 (3.6%) | 0.32 | |
| warfarin | 7 (15.2%) | 18 (5.2%) | 0.009 | 3 (11.1%) | 10 (5.2%) | 0.22 | |
| DOAC | 0 (0.0%) | 6 (1.7%) | 0.37 | 2 (7.4%) | 1 (0.5%) | 0.004 | |
| aspirin | 27 (58.7%) | 0 (0.0%) | <0.01 | 20 (74.1%) | 0 (0.0%) | <0.01 | |
| clopidogrel | 12 (26.1%) | 0 (0.0%) | <0.01 | 5 (18.5%) | 0 (0.0%) | <0.01 | |
| cilostazol | 8 (17.4%) | 0 (0.0%) | <0.01 | 4 (14.8%) | 0 (0.0%) | <0.01 | |
| prasugrel | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |||
| Discharge medicine | |||||||
| RAAS inhibitor | 21 (56.8%) | 212 (63.7%) | 0.41 | 14 (51.9%) | 158 (85.0%) | <0.01 | |
| CCB | 17 (46.0%) | 171 (51.4%) | 0.53 | 19 (70.4%) | 172 (92.5%) | <0.01 | |
| β-blocker | 32 (86.5%) | 262 (78.7%) | 0.26 | 23 (85.2%) | 168 (90.3%) | 0.41 | |
| diuretics | 13 (35.1%) | 111 (33.3%) | 0.83 | 5 (18.5%) | 50 (26.9%) | 0.35 | |
| α-blocker | 2 (5.4%) | 11 (3.3%) | 0.51 | 2 (7.4%) | 14 (7.5%) | 0.98 | |
| warfarin | 6 (15.8%) | 70 (20.9%) | 0.46 | 2 (7.4%) | 8 (4.3%) | 0.47 | |
| DOAC | 0 (0.0%) | 21 (6.3%) | 0.11 | 2 (7.4%) | 3 (1.6%) | 0.06 | |
| aspirin | 17 (44.7%) | 83 (24.8%) | 0.009 | 11 (40.7%) | 9 (4.8%) | <0.01 | |
| clopidogrel | 5 (13.2%) | 6 (1.8%) | <0.01 | 5 (18.5%) | 0 (0.0%) | <0.01 | |
| cilostazol | 4 (10.5%) | 2 (0.6%) | <0.01 | 1 (3.7%) | 0 (0.0%) | 0.008 | |
| prasugrel | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |||
Data are mean ± SE, or mean (%), JCS; Japan Coma Scale, A Fib; atrial fibrillation, CAD; coronary artery diseases, CVD; cardiovascular diseases, PAD; peripheral arterial diseases, VTE; venous thromboembolism, LV; left ventricular, HT; hypertension, DM; diabetes mellitus, DLp: dyslipidemia, AVR; aortic valve replacement, MVR; mitral valve replacement, CABG; coronary artery bypass grafting, RAAS; renin-angiotensin-aldosterone system, CCB; calcium channel blocker, DOAC; direct oral anti-coagulant. Genetic and others includes Marfan syndrome, Loeys-Dietz syndrome, and Behçet’s disease.
Table 4.
Cox proportional hazard model for all-cause mortality in TRANSFERRED acute aortic dissection patients.
Table 4.
Cox proportional hazard model for all-cause mortality in TRANSFERRED acute aortic dissection patients.
| Type A | β | SE | p-Value | Type B | β | SE | p-Value |
|---|---|---|---|---|---|---|---|
| Age | 0.01 | 0.01 | 0.23 | Age | 0.0005 | 0.02 | 0.98 |
| Sex | −0.02 | 0.23 | 0.94 | Sex | −0.64 | 0.65 | 0.32 |
| Systolic BP | −0.02 | <0.01 | <0.01 | Systolic BP | −0.03 | 0.01 | 0.02 |
| Diastolic BP | −0.01 | 0.008 | 0.19 | Diastolic BP | −0.02 | 0.02 | 0.24 |
| Heart rate | 0.011 | 0.006 | 0.05 | Heart rate | 0.03 | 0.01 | 0.04 |
| eGFR | −0.028 | 0.006 | <0.01 | eGFR | −0.02 | 0.01 | 0.04 |
| Surgery | −2.39 | 0.25 | <0.01 | Surgery | 0.77 | 0.59 | 0.19 |
| JCS | 0.86 | 0.1 | <0.01 | JCS | 1.23 | 0.25 | <0.01 |
| Past history | Past history | ||||||
| A Fib | −1.05 | 0.72 | 0.15 | A Fib | 1.93 | 0.67 | <0.01 |
| CAD | 0.76 | 0.4 | 0.06 | CAD | −14.08 | 1484 | 0.99 |
| Other CVD | 0.005 | 0.36 | 0.99 | Other CVD | 0.18 | 0.77 | 0.81 |
| PAD | 0.16 | 0.35 | 0.64 | PAD | 0.47 | 0.6 | 0.43 |
| VTE | −12.01 | 744.56 | 0.99 | VTE | 0 | ||
| LV dysfunction | −13.03 | 789.73 | 0.99 | LV dysfunction | 0 | ||
| HT | −0.8 | 0.31 | 0.01 | HT | 14.09 | 1400 | 0.99 |
| DM | −0.55 | 0.59 | 0.35 | DM | 0.12 | 0.77 | 0.87 |
| DLp | −0.23 | 0.33 | 0.49 | DLp | −0.04 | 0.66 | 0.95 |
| Genetic and others | 0.57 | 0.62 | 0.35 | Genetic and others | −14.07 | 1509 | 0.99 |
| Smoking | −0.64 | 0.31 | 0.04 | Smoking | 0.21 | 0.6 | 0.72 |
| Alcohol | −0.68 | 0.34 | 0.04 | Alcohol | −0.2 | 0.57 | 0.73 |
| post-AVR | 1.02 | 0.59 | 0.09 | post-AVR | −14.09 | 1577 | 0.99 |
| post-MVR | 0 | post-MVR | −11.01 | 1501 | 0.99 | ||
| CABG | −12.01 | 627.8 | 0.98 | CABG | −12.01 | 1543 | 0.99 |
| Intervention to aortic aneurysm and/or dissection | 0.27 | 0.47 | 0.57 | Intervention to aortic aneurysm and/or dissection | −0.45 | 1.04 | 0.67 |
| Complication | Complication | ||||||
| Major bleeding | 1.52 | 0.32 | <0.01 | Major bleeding | 3.87 | 0.59 | <0.01 |
| Infarction by aortic dissection | 1.54 | 0.27 | <0.01 | Infarction by aortic dissection | 2.04 | 0.57 | <0.01 |
| Paroxysmal A Fib | −1.66 | 0.52 | <0.01 | Paroxysmal A Fib | −14.09 | 1435 | 0.99 |
| Medication on admission | Medication on admission | ||||||
| RAAS inhibitor | −0.06 | 0.31 | 0.85 | RAAS inhibitor | −16.67 | 1711 | 0.99 |
| CCB | 0.36 | 0.29 | 0.22 | CCB | 0.14 | 0.61 | 0.82 |
| β-blocker | 0.04 | 0.39 | 0.93 | β-blocker | −0.2 | 0.78 | 0.8 |
| diuretics | 0.6 | 0.44 | 0.17 | diuretics | 1.9 | 0.79 | 0.02 |
| α-blocker | 1.2 | 0.52 | 0.02 | α-blocker | −14.05 | 1838 | 0.99 |
| warfarin | 0.16 | 0.53 | 0.77 | warfarin | 0.4 | 1.06 | 0.71 |
| DOAC | −13.03 | 787.37 | 0.99 | DOAC | −13.02 | 2047 | 0.99 |
| aspirin | 0.8 | 0.41 | 0.05 | aspirin | −15.16 | 1903 | 0.99 |
| clopidogrel | −14.17 | 771.42 | 0.99 | clopidogrel | −13.04 | 2043 | 0.99 |
| cilostazol | −13.03 | 673.45 | 0.98 | cilostazol | −13.05 | 1571 | 0.99 |
| prasugrel | 0 | prasugrel | 0 | ||||
| other anti-platelet drug | 1.18 | 1.01 | 0.24 | other anti-platelet drug | −12.01 | 2086 | 0.99 |
| Anti-coagulant (warfarin or DOAC) | −0.33 | 0.52 | 0.52 | Anti-coagulant (warfarin or DOAC) | −0.12 | 1.04 | 0.91 |
| Anti-platelet drug (aspirin, clopidogrel, cilostazol, or prasugrel) | −0.02 | 0.38 | 0.96 | Anti-platelet drug (aspirin, clopidogrel, cilostazol, or prasugrel) | −15.19 | 1457 | 0.99 |
| Both anti-coagulant and anti-platelet | 0.55 | 0.72 | 0.44 | Both anti-coagulant and anti-platelet | −13.03 | 1218 | 0.99 |
| Anti-coagulant or anti-platelet | −0.26 | 0.34 | 0.45 | Anti-coagulant or anti-platelet | −1.02 | 1.04 | 0.33 |
SE; standard error, HR, hazard ratio, BP; blood pressure, eGFR; estimated glomerular filtration rate, JCS; Japan Coma Scale, A Fib; atrial fibrillation, CAD; coronary artery diseases, CVD; cardiovascular diseases, PAD; peripheral arterial diseases, VTE; venous thromboembolism, LV; left ventricular, HT; hypertension, DM; diabetes mellitus, DLp: dyslipidemia, AVR; aortic valve replacement, MVR; mitral valve replacement, CABG; coronary artery bypass grafting, RAAS; renin-angiotensin-aldosterone system, CCB; calcium channel blocker, DOAC; direct oral anti-coagulant. Genetic and others includes Marfan syndrome, Loeys-Dietz syndrome, and Behçet’s disease.
Table 5.
Age and sex-adjusted Cox proportional hazard model for all-cause mortality in TRANSFERRED acute aortic dissection patients.
Table 5.
Age and sex-adjusted Cox proportional hazard model for all-cause mortality in TRANSFERRED acute aortic dissection patients.
| Type A (Age and Sex-Adjusted) | β | SE | p-Value | Type B (Age and Sex-Adjusted) | β | SE | p-Value |
|---|---|---|---|---|---|---|---|
| Systolic BP | −0.02 | 0.004 | <0.01 | Systolic BP | −0.03 | 0.01 | 0.01 |
| Diastolic BP | −0.01 | 0.008 | 0.17 | Diastolic BP | −0.02 | 0.02 | 0.18 |
| Heart rate | 0.01 | 0.006 | 0.07 | Heart rate | 0.03 | 0.02 | 0.05 |
| eGFR | −0.03 | 0.006 | <0.01 | eGFR | −0.02 | 0.01 | 0.02 |
| Surgery | −2.38 | 0.25 | <0.01 | Surgery | 0.85 | 0.59 | 0.15 |
| JCS | 0.85 | 0.1 | <0.01 | JCS | 1.23 | 0.26 | <0.01 |
| Past history | Past history | ||||||
| A Fib | −1.21 | 0.72 | 0.1 | A Fib | 2.05 | 0.69 | <0.01 |
| CAD | 0.7 | 0.4 | 0.09 | CAD | −14 | 1480 | 0.99 |
| Other CVD | −0.08 | 0.37 | 0.83 | Other CVD | 0.16 | 0.78 | 0.83 |
| PAD | 0.05 | 0.36 | 0.89 | PAD | 0.5 | 0.61 | 0.41 |
| VTE | −12.06 | 752.05 | 0.99 | VTE | 0 | ||
| LV dysfunction | −12.99 | 788.9 | 0.99 | LV dysfunction | 0 | ||
| HT | −0.88 | 0.32 | <0.01 | HT | 14.07 | 1400 | 0.99 |
| DM | −0.58 | 0.59 | 0.33 | DM | 0.17 | 0.77 | 0.82 |
| DLp | −0.2 | 0.34 | 0.56 | DLp | −0.02 | 0.66 | 0.98 |
| Genetic and others | 0.71 | 0.63 | 0.26 | Genetic and others | −14.11 | 1513 | 0.99 |
| Smoking | −0.86 | 0.36 | 0.02 | Smoking | −0.01 | 0.7 | 0.99 |
| Alcohol | −0.8 | 0.38 | 0.03 | Alcohol | −0.39 | 0.6 | 0.52 |
| post-AVR | 1.01 | 0.61 | 0.1 | post-AVR | −14.02 | 1587 | 0.99 |
| post-MVR | 0 | post-MVR | −11.13 | 1515 | 0.99 | ||
| CABG | −12.24 | 633.99 | 0.98 | CABG | −12.16 | 1558 | 0.99 |
| Intervention to aortic aneurysm and/or dissection | 0.18 | 0.49 | 0.72 | Intervention to aortic aneurysm and/or dissection | −0.41 | 1.05 | 0.7 |
| Complication | Complication | ||||||
| Major bleeding | 1.48 | 0.32 | <0.01 | Major bleeding | 4.24 | 0.71 | <0.01 |
| Infarction by aortic dissection | 1.52 | 0.27 | <0.01 | Infarction by aortic dissection | 2.04 | 0.57 | <0.01 |
| Paroxysmal A Fib | −1.75 | 0.52 | <0.01 | Paroxysmal A Fib | −13.95 | 1435 | 0.99 |
| Medication on admission | Medication on admission | ||||||
| RAAS inhibitor | −0.14 | 0.31 | 0.66 | RAAS inhibitor | −16.6 | 1710 | 0.99 |
| CCB | 0.29 | 0.29 | 0.33 | CCB | 0.33 | 0.63 | 0.6 |
| β-blocker | −0.05 | 0.39 | 0.89 | β-blocker | −0.05 | 0.78 | 0.94 |
| diuretics | 0.48 | 0.44 | 0.27 | diuretics | 1.83 | 0.79 | 0.02 |
| α-blocker | 1.16 | 0.52 | 0.03 | α-blocker | −13.97 | 1835 | 0.99 |
| warfarin | −0.002 | 0.54 | 0.99 | warfarin | 0.7 | 1.07 | 0.51 |
| DOAC | −13.24 | 796.32 | 0.99 | DOAC | −13.25 | 2020 | 0.99 |
| aspirin | 0.75 | 0.42 | 0.07 | aspirin | −15.33 | 1875 | 0.99 |
| clopidogrel | −14.35 | 776.75 | 0.99 | clopidogrel | −13.26 | 2052 | 0.99 |
| cilostazol | −13.12 | 675.96 | 0.98 | cilostazol | −13.68 | 1616 | 0.99 |
| prasugrel | 0 | prasugrel | 0 | ||||
| other anti-platelet drug | 1.14 | 1.02 | 0.27 | other anti-platelet drug | −12.41 | 2152 | 0.99 |
| Anti-coagulant (warfarin or DOAC) | −0.48 | 0.53 | 0.36 | Anti-coagulant (warfarin or DOAC) | 0.05 | 1.05 | 0.96 |
| Anti-platelet drug (aspirin, clopidogrel, cilostazol, or prasugrel) | −0.11 | 0.38 | 0.78 | Anti-platelet drug (aspirin, clopidogrel, cilostazol, or prasugrel) | −15.19 | 1449 | 0.99 |
| Both anti-coagulant and anti-platelet | 0.49 | 0.72 | 0.5 | Both anti-coagulant and anti-platelet | −13.01 | 1217 | 0.99 |
| Anti-coagulant or anti-platelet | −0.41 | 0.36 | 0.25 | Anti-coagulant or anti-platelet | −0.94 | 1.05 | 0.37 |
SE; standard error, HR, hazard ratio, BP; blood pressure, eGFR; estimated glomerular filtration rate, JCS; Japan Coma Scale, A Fib; atrial fibrillation, CAD; coronary artery diseases, CVD; cardiovascular diseases, PAD; peripheral arterial diseases, VTE; venous thromboembolism, LV; left ventricular, HT; hypertension, DM; diabetes mellitus, DLp: dyslipidemia, AVR; aortic valve replacement, MVR; mitral valve replacement, CABG; coronary artery bypass grafting, RAAS; renin-angiotensin-aldosterone system, CCB; calcium channel blocker, DOAC; direct oral anti-coagulant. Genetic and others includes Marfan syndrome, Loeys-Dietz syndrome, and Behçet’s disease.
Table 6.
Clinical characteristics of HOSPITALIZED acute aortic dissection with and without anti-thrombotic therapy.
Table 6.
Clinical characteristics of HOSPITALIZED acute aortic dissection with and without anti-thrombotic therapy.
| Stanford Type A (n = 424) | Stanford Type B (n = 226) | ||||||
|---|---|---|---|---|---|---|---|
| Anti-Thrombotic Therapy | Yes | No | p Value | Yes | No | p Value | |
| (During Hospitalization) | (n = 182) | (n = 242) | (n = 42) | (n = 184) | |||
| Hospital stay (days) | 36.9 ± 24.5 | 29.1± 23.8 | <0.01 | 35.6 ± 30.8 | 25.7 ±20.0 | 0.01 | |
| Age (years old) | 69.9 ± 11.3 | 68.3 ± 12.3 | 0.17 | 67.8 ± 15.0 | 66.4 ± 11.8 | 0.51 | |
| Sex (male) | 91 (50.0%) | 120 (49.6%) | 0.9 | 23 (54.8%) | 131 (71.2%) | 0.04 | |
| Surgical/endovascular treatment | 177 (97.3%) | 194 (80.2%) | <0.01 | 6 (14.3) | 25 (13.6) | 0.91 | |
| JCS | 0 | 140 (76.9%) | 173 (71.5%) | 0.52 | 41 (97.6%) | 174 (94.6%) | 0.82 |
| 1–3 | 24 (13.2%) | 34 (14.1%) | 1 (2.4%) | 7 (3.8%) | |||
| 10–30 | 12 (6.6%) | 22 (9.1%) | 0 (0.0%) | 2 (1.1%) | |||
| 100–300 | 6 (3.3%) | 13 (5.4%) | 0 (0.0%) | 1 (0.5%) | |||
| Medical history | |||||||
| A Fib | 25 (13.7%) | 9 (3.7%) | <0.01 | 6 (14.3%) | 4 (2.2%) | <0.01 | |
| CAD | 13 (7.1%) | 11 (4.6%) | 0.27 | 7 (16.7%) | 4 (2.2%) | <0.01 | |
| Other CVD | 34 (18.7%) | 27 (11.3%) | 0.03 | 9 (21.4%) | 20 (10.9%) | 0.06 | |
| PAD | 23 (12.6%) | 32 (13.5%) | 0.81 | 12 (28.6%) | 37 (20.1%) | 0.49 | |
| VTE | 2 (1.1%) | 0 (0.0%) | 0.11 | 0 (0.0%) | 0 (0.0%) | ||
| HT | 159 (87.4%) | 213 (90.3%) | 0.35 | 40 (95.2%) | 175 (95.1%) | 0.97 | |
| DM | 17 (9.3%) | 15 (6.4%) | 0.26 | 7 (17.1%) | 23 (12.5%) | 0.44 | |
| DLp | 37 (20.3%) | 55 (23.4%) | 0.45 | 16 (38.1%) | 39 (21.2%) | 0.02 | |
| Genetic and others | 7 (3.8%) | 1 (0.4%) | 0.01 | 4 (9.5%) | 4 (2.2%) | 0.02 | |
| Smoking | 65 (35.7%) | 95 (41.1%) | 0.26 | 23 (56.1%) | 122 (67.0%) | 0.18 | |
| Alcohol | 60 (33.0%) | 75 (32.6%) | 0.94 | 13 (31.7%) | 81 (44.5%) | 0.13 | |
| Surgical history | |||||||
| post-AVR | 5 (2.7%) | 2 (0.8%) | 0.13 | 6 (14.3%) | 1 (0.5%) | <0.01 | |
| post-MVR | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (0.5%) | 0.63 | ||
| CABG | 2 (1.1%) | 1 (0.4%) | 0.42 | 2 (4.8%) | 0 (0.0%) | <0.01 | |
| Intervention to aortic aneurysm and/or dissection | 13 (7.1%) | 10 (4.2%) | 0.2 | 10 (24.4%) | 17 (9.2%) | <0.01 | |
| Primary outcome | |||||||
| All-cause death | 4 (2.2%) | 39 (16.1%) | <0.001 | 1 (2.4%) | 9 (4.9%) | 0.48 | |
| Secondary outcomes | |||||||
| Major bleeding | 8 (4.5%) | 18 (7.8%) | 0.17 | 0 (0%) | 6 (3.3%) | 0.24 | |
| Infarction by aortic dissection | 45 (25.1%) | 41 (17.8%) | 0.07 | 4 (9.5%) | 16 (8.7%) | 0.86 | |
| Paroxysmal A Fib | 77 (43.0%) | 35 (15.2%) | <0.01 | 3 (7.1%) | 7 (3.8%) | 0.34 | |
| Medication on admission | |||||||
| RAAS inhibitor | 58 (35.4%) | 61 (29.3%) | 0.22 | 18 (42.9%) | 56 (31.3%) | 0.15 | |
| CCB | 55 (33.5%) | 66 (31.7%) | 0.71 | 12 (28.6%) | 54 (30.2%) | 0.84 | |
| β-blocker | 30 (18.3%) | 24 (11.5%) | 0.07 | 8 (19.0%) | 32 (17.9%) | 0.86 | |
| diuretics | 15 (9.2%) | 10 (4.8%) | 0.09 | 1 (2.4%) | 7 (3.9%) | 0.63 | |
| α-blocker | 2 (1.2%) | 7 (3.4%) | 0.18 | 0 (0%) | 7 (3.9%) | 0.19 | |
| warfarin | 20 (12.1%) | 4 (1.9%) | <0.01 | 10(23.8%) | 2 (1.1%) | <0.01 | |
| DOAC | 5 (3.0%) | 1 (0.5%) | 0.05 | 3 (7.1%) | 0 (0.0%) | <0.01 | |
| aspirin | 15 (9.0%) | 9 (4.3%) | 0.06 | 15 (35.7%) | 5 (2.8%) | <0.01 | |
| clopidogrel | 9 (5.4%) | 3 (1.4%) | 0.03 | 5 (11.9%) | 0 (0%) | <0.01 | |
| cilostazol | 4 (2.4%) | 4 (1.9%) | 0.74 | 3 (7.1%) | 1 (0.5%) | <0.01 | |
| prasugrel | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |||
| Discharge medicine | |||||||
| RAAS inhibitor | 107 (61.5%) | 126 (64.3%) | 0.58 | 28 (68.3%) | 144 (83.7%) | 0.02 | |
| CCB | 75 (43.1%) | 113 (57.7%) | <0.01 | 31 (75.6%) | 160 (93.0%) | <0.01 | |
| β-blocker | 146 (83.9%) | 148 (75.5%) | 0.046 | 35 (85.4%) | 156 (90.7%) | 0.31 | |
| diuretics | 54 (31.0%) | 70 (35.7%) | 0.34 | 11 (26.8%) | 44 (25.6%) | 0.87 | |
| α-blocker | 5 (2.9%) | 8 (4.1%) | 0.53 | 3 (7.3%) | 13 (7.6%) | 0.96 | |
| warfarin | 76 (42.7%) | 0 (0.0%) | <0.01 | 10 (24.4%) | 0 (0.0%) | <0.01 | |
| DOAC | 21 (11.8%) | 0 (0.0%) | <0.01 | 5 (12.2%) | 0 (0.0%) | <0.01 | |
| aspirin | 100 (56.2%) | 0 (0.0%) | <0.01 | 20 (48.8%) | 0 (0.0%) | <0.01 | |
| clopidogrel | 11 (6.2%) | 0 (0.0%) | <0.01 | 5 (12.2%) | 0 (0.0%) | <0.01 | |
| cilostazol | 6 (3.4%) | 0 (0.0%) | <0.01 | 1 (2.4%) | 0 (0.0%) | 0.04 | |
| prasugrel | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |||
Data are mean ± SE, or mean (%), JCS; Japan Coma Scale, A Fib; atrial fibrillation, CAD; coronary artery diseases, CVD; cardiovascular diseases, PAD; peripheral arterial diseases, VTE; venous thromboembolism, LV; left ventricular, HT; hypertension, DM; diabetes mellitus, DLp: dyslipidemia, AVR; aortic valve replacement, MVR; mitral valve replacement, CABG; coronary artery bypass grafting, RAAS; renin-angiotensin-aldosterone system, CCB; calcium channel blocker, DOAC; direct oral anti-coagulant. Genetic and others includes Marfan syndrome, Loeys-Dietz syndrome, and Behçet’s disease.
Table 7.
Clinical characteristics of HOSPITALIZED acute aortic dissection with and without anti-coagulant therapy.
Table 7.
Clinical characteristics of HOSPITALIZED acute aortic dissection with and without anti-coagulant therapy.
| Anti-Coagulant Therapy | Stanford Type A (n = 424) | Stanford Type B (n = 226) | |||||
|---|---|---|---|---|---|---|---|
| Yes | No | p Value | Yes | No | p Value | ||
| (During Hospitalization) | (n = 109) | (n = 315) | (n = 16) | (n = 210) | |||
| Hospital stay (days) | 38.3 ± 23.9 | 30.4 ± 24.3 | 0.004 | 36.5 ± 37.8 | 26.3 ± 20.2 | 0.3 | |
| Age (years old) | 70.3 ± 11.3 | 68.6 ± 12.1 | 0.2 | 66.1 ± 18.4 | 66.7 ± 12.0 | 0.91 | |
| Sex (male) | 50 (45.9%) | 161 (51.1%) | 0.35 | 9 (56.3%) | 145 (69.1%) | 0.29 | |
| Surgical/endovascular treatment | 104 (95.4%) | 267 (84.8%) | 0.004 | 2 (12.5%) | 29 (13.8%) | 0.88 | |
| JCS | 0 | 85 (78.0%) | 228 (72.4%) | 0.61 | 15 (93.8%) | 200 (95.2%) | 0.9 |
| 1–3 | 13 (11.9%) | 45 (14.3%) | 1 (6.3%) | 7 (3.3%) | |||
| 10–30 | 6 (5.5%) | 28 (8.9%) | 0 (0.0%) | 2 (1.0%) | |||
| 100–300 | 5 (4.6%) | 14 (4.4%) | 0 (0.0%) | 1 (0.5%) | |||
| Medical history | |||||||
| A Fib | 23 (21.1%) | 11 (3.5%) | <0.01 | 6 (37.5%) | 4 (1.9%) | <0.01 | |
| CAD | 7 (6.4%) | 17 (5.5%) | 0.71 | 0 (0.0%) | 11 (5.2%) | 0.35 | |
| Other CVD | 19 (17.4%) | 42 (13.5%) | 0.31 | 1 (6.3%) | 28 (13.3%) | 0.41 | |
| PAD | 13 (11.9%) | 42 (13.5%) | 0.67 | 6 (37.5%) | 43 (20.5%) | 0.11 | |
| VTE | 2 (1.8%) | 0 (0.0%) | 0.02 | 0 (0.0%) | 0 (0.0%) | ||
| HT | 98 (89.9%) | 274 (88.7%) | 0.72 | 15 (93.8%) | 200 (95.2%) | 0.79 | |
| DM | 12 (11.0%) | 20 (6.5%) | 0.13 | 3 (18.8%) | 27 (12.9%) | 0.51 | |
| DLp | 24 (22.0%) | 68 (22.1%) | 0.99 | 5 (31.3%) | 50 (23.8%) | 0.5 | |
| Genetic and others | 7 (6.4%) | 1 (0.3%) | <0.01 | 3 (18.8%) | 5 (2.4%) | <0.01 | |
| Smoking | 33 (30.3%) | 127 (41.8%) | 0.03 | 7 (43.8%) | 138 (66.7%) | 0.06 | |
| Alcohol | 30 (27.5%) | 105 (34.6%) | 0.17 | 6 (37.5%) | 88 (42.5%) | 0.7 | |
| Surgical history | |||||||
| post-AVR | 3 (2.8%) | 4 (1.3%) | 0.31 | 5 (31.3%) | 2 (1.0%) | <0.01 | |
| post-MVR | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (0.5%) | 0.78 | ||
| CABG | 0 (0.0%) | 3 (1.0%) | 0.3 | 0 (0.0%) | 2 (1.0%) | 0.7 | |
| Intervention to aortic aneurysm and/or dissection | 7 (6.4%) | 16 (5.2%) | 0.62 | 3 (18.8%) | 24 (11.5%) | 0.39 | |
| Primary outcome | |||||||
| All-cause death | 3 (2.8%) | 40 (12.7%) | 0.003 | 0 (0.0%) | 10 (4.8%) | 0.37 | |
| Secondary outcomes | |||||||
| Major bleeding | 6 (5.7%) | 20 (6.6%) | 0.74 | 0 (0.0%) | 6 (2.9%) | 0.49 | |
| Infarction by aortic dissection | 24 (22.6%) | 62 (20.4%) | 0.62 | 0 (0.0%) | 20 (9.5%) | 0.2 | |
| Paroxysmal A Fib | 59 (55.7%) | 53 (17.4%) | <0.01 | 3 (18.8%) | 7 (3.3%) | 0.004 | |
| Medication on admission | |||||||
| RAAS inhibitor | 36 (37.1%) | 83 (30.2%) | 0.21 | 5 (31.3%) | 69 (33.7%) | 0.84 | |
| CCB | 38 (39.2%) | 83 (30.2%) | 0.1 | 4 (25.0%) | 62 (30.2%) | 0.66 | |
| β-blocker | 20 (20.6%) | 34 (12.4%) | 0.047 | 6 (37.5%) | 34 (16.6%) | 0.04 | |
| diuretics | 12 (12.4%) | 13 (4.7%) | 0.01 | 0 (0.0%) | 8 (3.9%) | 0.42 | |
| α-blocker | 1 (1.0%) | 8 (2.9%) | 0.3 | 0 (0.0%) | 7 (3.4%) | 0.45 | |
| warfarin | 17 (17.2%) | 7 (2.5%) | <0.01 | 8 (50.0%) | 4 (2.0%) | <0.01 | |
| DOAC | 5 (5.1%) | 1 (0.4%) | 0.001 | 3 (18.8%) | 0 (0.0%) | <0.01 | |
| aspirin | 7 (7.1%) | 17 (6.2%) | 0.75 | 4 (25.0%) | 16 (7.9%) | 0.02 | |
| clopidogrel | 1 (1.0%) | 11 (4.0%) | 0.15 | 0 (0.0%) | 5 (2.5%) | 0.53 | |
| cilostazol | 1 (1.0%) | 7 (2.5%) | 0.37 | 0 (0.0%) | 4 (2.0%) | 0.57 | |
| prasugrel | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |||
| Discharge medicine | |||||||
| RAAS inhibitor | 60 (58.8%) | 173 (64.6%) | 0.31 | 11 (68.8%) | 161 (81.7%) | 0.21 | |
| CCB | 44 (43.1%) | 144 (53.7%) | 0.07 | 13 (81.3%) | 178 (90.4%) | 0.25 | |
| β-blocker | 86 (84.3%) | 208 (77.6%) | 0.15 | 14 (87.5%) | 177 (89.9%) | 0.77 | |
| diuretics | 35 (34.3%) | 89 (33.2%) | 0.84 | 3 (18.8%) | 52 (26.4%) | 0.5 | |
| α-blocker | 2 (2.0%) | 11 (4.1%) | 0.32 | 1 (6.3%) | 15 (7.6%) | 0.84 | |
| warfarin | 76 (71.7%) | 0 (0.0%) | <0.01 | 10 (62.5%) | 0 (0.0%) | <0.01 | |
| DOAC | 21 (19.8%) | 0 (0.0%) | <0.01 | 5 (31.3%) | 0 (0.0%) | <0.01 | |
| aspirin | 41 (38.7%) | 59 (22.1%) | 0.001 | 1 (6.3%) | 19 (9.6%) | 0.66 | |
| clopidogrel | 2 (1.9%) | 9 (3.4%) | 0.44 | 0 (0.0%) | 5 (2.5%) | 0.52 | |
| cilostazol | 2 (1.9%) | 4 (1.5%) | 0.79 | 0 (0.0%) | 1 (0.5%) | 0.78 | |
| prasugrel | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |||
Data are mean ± SE, or mean (%), JCS; Japan Coma Scale, A Fib; atrial fibrillation, CAD; coronary artery diseases, CVD; cardiovascular diseases, PAD; peripheral arterial diseases, VTE; venous thromboembolism, LV; left ventricular, HT; hypertension, DM; diabetes mellitus, DLp: dyslipidemia, AVR; aortic valve replacement, MVR; mitral valve replacement, CABG; coronary artery bypass grafting, RAAS; renin-angiotensin-aldosterone system, CCB; calcium channel blocker, DOAC; direct oral anti-coagulant. Genetic and others includes Marfan syndrome, Loeys-Dietz syndrome, and Behçet’s disease.
Table 8.
Clinical characteristics of HOSPITALIZED acute aortic dissection with and without anti-platelet therapy.
Table 8.
Clinical characteristics of HOSPITALIZED acute aortic dissection with and without anti-platelet therapy.
| Anti-Platelet Therapy | Stanford Type A (n = 424) | Stanford Type B (n = 226) | |||||
|---|---|---|---|---|---|---|---|
| Yes | No | p Value | Yes | No | p Value | ||
| (During Hospitalization) | (n = 118) | (n = 306) | (n = 27) | (n = 199) | |||
| Hospital stay (days) | 36.3 ± 23.6 | 31.0 ± 24.6 | 0.04 | 31.5 ± 21.5 | 26.5 ± 22.0 | 0.26 | |
| Age (years old) | 68.3 ± 12.2 | 69.3 ± 11.8 | 0.4 | 69.4 ± 12.8 | 66.3 ± 12.4 | 0.23 | |
| Sex (male) | 53 (44.9%) | 160 (52.3%) | 0.17 | 12 (44.4%) | 60 (30.2%) | 0.13 | |
| Surgical/endovascular treatment | 117 (99.2%) | 254 (83.0%) | <0.01 | 4 (14.8%) | 27 (13.6%) | 0.86 | |
| JCS | 0 | 92 (77.9%) | 221 (72.2%) | 0.54 | 27 (100.0%) | 188 (94.5%) | 0.67 |
| 1–3 | 15 (12.7%) | 43 (14.1%) | 0 (0.0%) | 8 (4.0%) | |||
| 10–30 | 8 (6.8%) | 26 (8.5%) | 0 (0.0%) | 2 (1.0%) | |||
| 100–300 | 3 (2.5%) | 16 (5.2%) | 0 (0.0%) | 1 (0.5%) | |||
| Medical history | |||||||
| A Fib | 7 (5.9%) | 27 (8.9%) | 0.31 | 0 (0.0%) | 10 (5.0%) | 0.23 | |
| CAD | 11 (9.3%) | 13 (4.3%) | 0.046 | 7 (25.9%) | 4 (2.0%) | <0.01 | |
| Other CVD | 24 (20.3%) | 37 (12.2%) | 0.03 | 8 (29.6%) | 21 (10.6%) | 0.005 | |
| PAD | 14 (11.9%) | 41 (13.6%) | 0.64 | 7 (25.9%) | 42 (21.1%) | 0.57 | |
| VTE | 1 (0.9%) | 1 (0.3%) | 0.49 | 0 (0.0%) | 0 (0.0%) | ||
| HT | 96 (81.4%) | 276 (92.0%) | 0.002 | 26 (96.3%) | 189 (95.0%) | 0.76 | |
| DM | 8 (6.8%) | 24 (8.0%) | 0.67 | 4 (15.4%) | 26 (13.1%) | 0.74 | |
| DLp | 24 (20.3%) | 68 (22.7%) | 0.59 | 11 (40.7%) | 44 (22.1%) | 0.03 | |
| Genetic and others | 5 (4.2%) | 3 (1.0%) | 0.03 | 1 (3.7%) | 7 (3.5%) | 0.96 | |
| Smoking | 49 (41.5%) | 111 (37.6%) | 0.46 | 17 (65.4%) | 128 (65.0%) | 0.97 | |
| Alcohol | 45 (38.1%) | 90 (30.6%) | 0.14 | 8 (30.8%) | 86 (43.7%) | 0.21 | |
| Surgical history | |||||||
| post-AVR | 3 (2.5%) | 4 (1.3%) | 0.39 | 1 (3.7%) | 6 (3.0%) | 0.85 | |
| post-MVR | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (0.5%) | 0.71 | ||
| CABG | 2 (1.7%) | 1 (0.3%) | 0.14 | 2 (7.4%) | 0 (0.0%) | <0.01 | |
| Intervention to aortic aneurysm and/or dissection | 10 (8.5%) | 13 (4.3%) | 0.09 | 7 (26.9%) | 20 (10.1%) | 0.01 | |
| Primary outcome | |||||||
| All-cause death | 1 (0.9%) | 42 (13.7%) | <0.01 | 1 (3.7%) | 9 (4.5%) | 0.85 | |
| Secondary outcomes | |||||||
| Major bleeding | 5 (4.3%) | 21 (7.2%) | 0.28 | 0 (0.0%) | 6 (3.0%) | 0.36 | |
| Infarction by aortic dissection | 31 (26.5%) | 55 (18.8%) | 0.08 | 4 (14.8%) | 16 (8.0%) | 0.24 | |
| Paroxysmal A Fib | 36 (30.8%) | 76 (25.9%) | 0.32 | 0 (0,0%) | 10 (5.0%) | 0.23 | |
| Medication on admission | |||||||
| RAAS inhibitor | 36 (33.6%) | 83 (31.3%) | 0.66 | 13 (48.2%) | 61 (31.4%) | 0.08 | |
| CCB | 30 (28.0%) | 91 (34.3%) | 0.24 | 8 (29.6%) | 58 (29.9%) | 0.98 | |
| β-blocker | 18 (16.8%) | 36 (13.6%) | 0.42 | 2 (7.4%) | 38 (19.6%) | 0.12 | |
| diuretics | 8 (7.6%) | 17 (6.4%) | 0.69 | 1 (3.7%) | 7 (3.6%) | 0.98 | |
| α-blocker | 1 (0.9%) | 8 (3.0%) | 0.24 | 0 (0.0%) | 7 (3.6%) | 0.32 | |
| warfarin | 13 (12.0%) | 11 (4.1%) | 0.005 | 2 (7.4%) | 10 (5.2%) | 0.64 | |
| DOAC | 0 (0.0%) | 6 (2.3%) | 0.12 | 0 (0.0%) | 3 (1.6%) | 0.51 | |
| aspirin | 14 (13.0%) | 10 (3.8%) | 0.001 | 11 (40.7%) | 9 (4.7%) | <0.01 | |
| clopidogrel | 9 (8.3%) | 3 (1.1%) | <0.01 | 5 (18.5%) | 0 (0.0%) | <0.01 | |
| cilostazol | 4 (3.7%) | 4 (1.5%) | 0.18 | 3 (11.1%) | 1 (0.5%) | <0.01 | |
| prasugrel | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |||
| Discharge medicine | |||||||
| RAAS inhibitor | 74 (64.9%) | 159 (62.1%) | 0.61 | 18 (69.2%) | 154 (82.4%) | 0.11 | |
| CCB | 52 (45.6%) | 136 (53.1%) | 0.18 | 19 (73.1%) | 172 (92.0%) | 0.003 | |
| β-blocker | 96 (84.2%) | 198 (77.3%) | 0.13 | 22 (84.6%) | 169 (90.4%) | 0.37 | |
| diuretics | 34 (29.8%) | 90 (35.2%) | 0.32 | 8 (30.8%) | 47 (25.1%) | 0.54 | |
| α-blocker | 4 (3.5%) | 9 (3.5%) | 0.99 | 2 (7.7%) | 14 (7.5%) | 0.97 | |
| warfarin | 34 (29.1%) | 42 (16.4%) | 0.005 | 0 (0.0%) | 10 (5.3%) | 0.23 | |
| DOAC | 4 (3.4%) | 17 (6.6%) | 0.21 | 0 (0.0%) | 5 (2.7%) | 0.4 | |
| aspirin | 99 (84.6%) | 1 (0.4%) | <0.01 | 20 (76.9%) | 0 (0.0%) | <0.01 | |
| clopidogrel | 11 (9.4%) | 0 (0.0%) | <0.01 | 5 (19.2%) | 0 (0.0%) | <0.01 | |
| cilostazol | 6 (5.1%) | 0 (0.0%) | <0.01 | 1 (3.9%) | 0 (0.0%) | 0.007 | |
| prasugrel | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |||
Data are mean ± SE, or mean (%), JCS; Japan Coma Scale, A Fib; atrial fibrillation, CAD; coronary artery diseases, CVD; cardiovascular diseases, PAD; peripheral arterial diseases, VTE; venous thromboembolism, LV; left ventricular, HT; hypertension, DM; diabetes mellitus, DLp: dyslipidemia, AVR; aortic valve replacement, MVR; mitral valve replacement, CABG; coronary artery bypass grafting, RAAS; renin-angiotensin-aldosterone system, CCB; calcium channel blocker, DOAC; direct oral anti-coagulant. Genetic and others includes Marfan syndrome, Loeys-Dietz syndrome, and Behçet’s disease.
Table 9.
Cox proportional hazard model for all-cause mortality in HOSPITALIZED acute aortic dissection patients.
Table 9.
Cox proportional hazard model for all-cause mortality in HOSPITALIZED acute aortic dissection patients.
| Type A | β | SE | p-Value | Type B | β | SE | p-Value |
|---|---|---|---|---|---|---|---|
| Age | 0.006 | 0.01 | 0.65 | Age | 0.004 | 0.025 | 0.88 |
| Sex | −0.11 | 0.31 | 0.72 | Sex | −0.65 | 0.79 | 0.41 |
| Systolic BP | −0.02 | 0.006 | <0.01 | Systolic BP | −0.011 | 0.014 | 0.4 |
| Diastolic BP | −0.005 | 0.01 | 0.63 | Diastolic BP | −0.002 | 0.018 | 0.9 |
| Heart rate | 0.01 | 0.008 | 0.11 | Heart rate | 0.033 | 0.016 | 0.04 |
| eGFR | −0.028 | 0.007 | <0.01 | eGFR | −0.022 | 0.012 | 0.08 |
| Surgery | −1.7 | 0.33 | <0.01 | Surgery | 0.38 | 0.8 | 0.63 |
| JCS | 0.82 | 0.13 | <0.01 | JCS | 1.04 | 0.42 | 0.01 |
| Past history | Past history | ||||||
| A Fib | −1.34 | 1.01 | 0.19 | A Fib | 1.79 | 0.8 | 0.03 |
| CAD | 0.67 | 0.53 | 0.21 | CAD | −14.08 | 1721 | 0.99 |
| Other CVD | 0.22 | 0.42 | 0.6 | Other CVD | −15.23 | 1650 | 0.99 |
| PAD | 0.04 | 0.45 | 0.93 | PAD | 0.44 | 0.69 | 0.53 |
| VTE | −12.01 | 915.23 | 0.99 | VTE | 0 | ||
| LV dysfunction | −13.04 | 930.19 | 0.99 | LV dysfunction | 0 | ||
| HT | −0.28 | 0.48 | 0.56 | HT | 14.1 | 1594 | 0.99 |
| DM | −0.56 | 0.73 | 0.44 | DM | −0.38 | 1.06 | 0.72 |
| DLp | −0.23 | 0.42 | 0.58 | DLp | −1.02 | 1.05 | 0.33 |
| Genetic and others | 0.47 | 0.77 | 0.54 | Genetic and others | −14.07 | 1681 | 0.99 |
| Smoking | −0.52 | 0.36 | 0.15 | Smoking | 0.26 | 0.69 | 0.71 |
| Alcohol | −0.52 | 0.38 | 0.18 | Alcohol | −0.15 | 0.65 | 0.82 |
| post-AVR | 1.03 | 0.73 | 0.16 | post-AVR | −14.1 | 1749 | 0.99 |
| post-MVR | 0 | post-MVR | −11.01 | 2104 | 0.99 | ||
| CABG | −12.01 | 776.4 | 0.99 | CABG | −12.01 | 1962 | 0.99 |
| Intervention to aortic aneurysm and/or dissection | 0.1 | 0.61 | 0.87 | Intervention to aortic aneurysm and/or dissection | −15.21 | 1776 | 0.99 |
| Complication | Complication | ||||||
| Major bleeding | 1.66 | 0.38 | <0.01 | Major bleeding | 3.82 | 0.68 | <0.01 |
| Infarction by aortic dissection | 1.63 | 0.33 | <0.01 | Infarction by aortic dissection | 2.58 | 0.66 | <0.01 |
| Paroxysmal A Fib | −1.27 | 0.53 | 0.02 | Paroxysmal A Fib | −14.1 | 1623 | 0.99 |
| Medication on admission | Medication on admission | ||||||
| RAAS inhibitor | −0.073 | 0.38 | 0.85 | RAAS inhibitor | −16.67 | 1876 | 0.99 |
| CCB | 0.54 | 0.35 | 0.12 | CCB | −0.014 | 0.69 | 0.98 |
| β-blocker | −0.1 | 0.49 | 0.84 | β-blocker | −0.81 | 1.06 | 0.44 |
| diuretics | 0.58 | 0.54 | 0.28 | diuretics | −14.05 | 2135 | 0.99 |
| α-blocker | 1.32 | 0.61 | 0.03 | α-blocker | −14.05 | 2021 | 0.99 |
| warfarin | 0.23 | 0.61 | 0.71 | warfarin | −15.13 | 2435 | 0.99 |
| DOAC | −13.03 | 969.9 | 0.99 | DOAC | −13.02 | 2372 | 0.99 |
| aspirin | 0.61 | 0.54 | 0.26 | aspirin | −15.17 | 2114 | 0.99 |
| clopidogrel | −14.21 | 884.34 | 0.99 | clopidogrel | −12.03 | 1628 | 0.99 |
| cilostazol | −13.04 | 823.72 | 0.99 | cilostazol | −13.06 | 1757 | 0.99 |
| prasugrel | 0 | prasugrel | 0 | ||||
| other anti-platelet drug | 1.69 | 1.02 | 0.1 | other anti-platelet drug | −12.01 | 2395 | 0.99 |
| Anti-thrombus during hospitalization | Anti-thrombus during hospitalization | ||||||
| Anti-coagulant (warfarin or DOAC) | −1.62 | 0.6 | <0.01 | Anti-coagulant (warfarin or DOAC) | −15.13 | 2087 | 0.99 |
| Anti-platelet drug (aspirin, clopidogrel, cilostazol, or prasugrel) | −2.88 | 1.01 | <0.01 | Anti-platelet drug (aspirin, clopidogrel, cilostazol, or prasugrel) | −0.38 | 1.06 | 0.72 |
| Both anti-coagulant and anti-platelet | −15.2 | 860.56 | 0.99 | Both anti-coagulant and anti-platelet | −12.01 | 1770 | 0.99 |
| Anti-coagulant or anti-platelet | −2.12 | 0.53 | <0.01 | Anti-coagulant or anti-platelet | −0.91 | 1.06 | 0.39 |
SE; standard error, HR, hazard ratio, BP; blood pressure, eGFR; estimated glomerular filtration rate, JCS; Japan Coma Scale, A Fib; atrial fibrillation, CAD; coronary artery diseases, CVD; cardiovascular diseases, PAD; peripheral arterial diseases, VTE; venous thromboembolism, LV; left ventricular, HT; hypertension, DM; diabetes mellitus, DLp: dyslipidemia, AVR; aortic valve replacement, MVR; mitral valve replacement, CABG; coronary artery bypass grafting, RAAS; renin-angiotensin-aldosterone system, CCB; calcium channel blocker, DOAC; direct oral anti-coagulant. Genetic and others includes Marfan syndrome, Loeys-Dietz syndrome, and Behçet’s disease.
Table 10.
Age and sex-adjusted Cox proportional hazard model for all-cause mortality in HOSPITALIZED acute aortic dissection patients.
Table 10.
Age and sex-adjusted Cox proportional hazard model for all-cause mortality in HOSPITALIZED acute aortic dissection patients.
| Type A (Age and Sex-Adjusted) | β | SE | p-Value | Type B (Age and Sex-Adjusted) | β | SE | p-Value |
|---|---|---|---|---|---|---|---|
| Systolic BP | −0.02 | 0.006 | <0.01 | Systolic BP | −0.012 | 0.014 | 0.37 |
| Diastolic BP | −0.005 | 0.01 | 0.61 | Diastolic BP | −0.005 | 0.019 | 0.79 |
| Heart rate | 0.012 | 0.008 | 0.12 | Heart rate | 0.035 | 0.018 | 0.05 |
| eGFR | −0.028 | 0.007 | <0.01 | eGFR | −0.025 | 0.013 | 0.05 |
| Surgery | −1.7 | 0.33 | <0.01 | Surgery | 0.48 | 0.8 | 0.55 |
| JCS | 0.83 | 0.13 | <0.01 | JCS | 1.03 | 0.43 | 0.02 |
| Past history | Past history | ||||||
| A Fib | −1.48 | 1.02 | 0.15 | A Fib | 1.87 | 0.83 | 0.02 |
| CAD | 0.63 | 0.53 | 0.23 | CAD | −13.99 | 1722 | 0.99 |
| Other CVD | 0.17 | 0.42 | 0.69 | Other CVD | −15.32 | 1649 | 0.99 |
| PAD | −0.04 | 0.46 | 0.93 | PAD | 0.44 | 0.71 | 0.53 |
| VTE | −12.04 | 919.33 | 0.99 | VTE | 0 | ||
| LV dysfunction | −13.02 | 930.55 | 0.99 | LV dysfunction | 0 | ||
| HT | −0.33 | 0.48 | 0.5 | HT | 14.09 | 1589 | 0.99 |
| DM | −0.58 | 0.73 | 0.42 | DM | −0.32 | 1.06 | 0.76 |
| DLp | −0.2 | 0.42 | 0.63 | DLp | −1 | 1.06 | 0.34 |
| Genetic and others | 0.58 | 0.78 | 0.46 | Genetic and others | −13.84 | 1682 | 0.99 |
| Smoking | −0.78 | 0.42 | 0.06 | Smoking | −0.099 | 0.8 | 0.9 |
| Alcohol | −0.65 | 0.43 | 0.13 | Alcohol | −0.42 | 0.68 | 0.54 |
| post-AVR | 1.004 | 0.75 | 0.18 | post-AVR | −13.79 | 1754 | 0.99 |
| post-MVR | 0 | post-MVR | −11.24 | 2140 | 0.99 | ||
| CABG | −12.14 | 778.45 | 0.99 | CABG | −12.21 | 1995 | 0.99 |
| Intervention to aortic aneurysm and/or dissection | 0.019 | 0.63 | 0.98 | Intervention to aortic aneurysm and/or dissection | −15.16 | 1769 | 0.99 |
| Complication | Complication | ||||||
| Major bleeding | 1.62 | 0.39 | <0.01 | Major bleeding | 4.17 | 0.81 | <0.01 |
| Infarction by aortic dissection | 1.64 | 0.33 | <0.01 | Infarction by aortic dissection | 2.6 | 0.66 | <0.01 |
| Paroxysmal A Fib | −1.34 | 0.53 | 0.01 | Paroxysmal A Fib | −13.95 | 1622 | 0.99 |
| Medication on admission | Medication on admission | ||||||
| RAAS inhibitor | −0.11 | 0.38 | 0.77 | RAAS inhibitor | −16.64 | 1879 | 0.99 |
| CCB | 0.52 | 0.36 | 0.14 | CCB | 0.14 | 0.71 | 0.85 |
| β-blocker | −0.15 | 0.49 | 0.76 | β-blocker | −0.7 | 1.02 | 0.51 |
| diuretics | 0.52 | 0.54 | 0.34 | diuretics | −14.13 | 2151 | 0.99 |
| α-blocker | 1.31 | 0.61 | 0.03 | α-blocker | −13.99 | 2021 | 0.99 |
| warfarin | 0.14 | 0.63 | 0.83 | warfarin | −14.86 | 2386 | 0.99 |
| DOAC | −13.12 | 972.53 | 0.99 | DOAC | −13.32 | 2347 | 0.99 |
| aspirin | 0.55 | 0.55 | 0.31 | aspirin | −15.46 | 2096 | 0.99 |
| clopidogrel | −14.39 | 881.58 | 0.99 | clopidogrel | −12.25 | 1637 | 0.99 |
| cilostazol | −13.05 | 824.28 | 0.99 | cilostazol | −13.7 | 1797 | 0.99 |
| prasugrel | 0 | prasugrel | 0 | ||||
| other anti-platelet drug | 1.62 | 1.03 | 0.12 | other anti-platelet drug | −12.37 | 2454 | 0.99 |
| Anti-thrombus during hospitalization | Anti-thrombus during hospitalization | ||||||
| Anti-coagulant (warfarin or DOAC) | −1.64 | 0.6 | <0.01 | Anti-coagulant (warfarin or DOAC) | −15.03 | 2073 | 0.99 |
| Anti-platelet drug (aspirin, clopidogrel, cilostazol, or prasugrel) | −2.9 | 1.01 | <0.01 | Anti-platelet drug (aspirin, clopidogrel, cilostazol, or prasugrel) | −0.31 | 1.08 | 0.78 |
| Both anti-coagulant and anti-platelet | −15.19 | 859.87 | 0.99 | Both anti-coagulant and anti-platelet | −12.29 | 1802 | 0.99 |
| Anti-coagulant or anti-platelet | −2.17 | 0.53 | <0.01 | Anti-coagulant or anti-platelet | −0.82 | 1.08 | 0.44 |
SE; standard error, HR, hazard ratio, BP; blood pressure, eGFR; estimated glomerular filtration rate, JCS; Japan Coma Scale, A Fib; atrial fibrillation, CAD; coronary artery diseases, CVD; cardiovascular diseases, PAD; peripheral arterial diseases, VTE; venous thromboembolism, LV; left ventricular, HT; hypertension, DM; diabetes mellitus, DLp: dyslipidemia, AVR; aortic valve replacement, MVR; mitral valve replacement, CABG; coronary artery bypass grafting, RAAS; renin-angiotensin-aldosteron system, CCB; calcium channel blocker, DOAC; direct oral anti-coagulant. Genetic and others includes Marfan syndrome, Loeys-Dietz syndrome, and Behçet’s disease.
Table 11.
All-cause death of anti-thrombotic agents administered during hospitalization in HOSPITALIZED patients.
Table 11.
All-cause death of anti-thrombotic agents administered during hospitalization in HOSPITALIZED patients.
| Stanford type A | Administered during hospitalization | |||
| State on admission | no | yes | p value | |
| Anti-coagulants | no | n = 307 | n = 87 (a) | |
| All-cause death | 37 (12.1%) | 3 (3.5%) | 0.02 | |
| yes | n = 8 | n = 22 (b) | ||
| All-cause death | 3 (37.5%) | 0 (0.0%) | 0.003 | |
| Anti-platelets | no | n = 288 | n = 93 (a) | |
| All-cause death | 38 (13.2%) | 0 (0.0%) | <0.01 | |
| yes | n = 18 | n = 25 (b) | ||
| All-cause death | 4 (22.2%) | 1 (4.0%) | 0.07 | |
| Stanford type B | Administered during hospitalization | |||
| State on admission | no | yes | p value | |
| Anti-coagulants | no | n = 206 | n = 5 (a) | |
| All-cause death | 10 (4.9%) | 0 (0.0%) | 0.6 | |
| yes | n = 4 | n = 11 (b) | ||
| All-cause death | 0 (0.0%) | 0 (0.0%) | N/A | |
| Anti-platelets | no | n = 188 | n = 11 (a) | |
| All-cause death | 9 (4.8%) | 1 (9.1%) | 0.5 | |
| yes | n = 11 | n = 16 (b) | ||
| All-cause death | 0 (0.0%) | 0 (0.0%) | N/A | |
(a): newly administered during hospitalization, (b): continued during hospitalization, All-cause death; number (%).
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Hori, K.; Morikawa, N.; Tayama, E.; Fukumoto, Y. Use of Anti-Thrombotic Drugs and In-Hospital Mortality in Acute Aortic Dissection Patients. Diagnostics 2022, 12, 2322. https://doi.org/10.3390/diagnostics12102322
AMA Style
Hori K, Morikawa N, Tayama E, Fukumoto Y. Use of Anti-Thrombotic Drugs and In-Hospital Mortality in Acute Aortic Dissection Patients. Diagnostics. 2022; 12(10):2322. https://doi.org/10.3390/diagnostics12102322
Chicago/Turabian StyleHori, Kensuke, Nagisa Morikawa, Eiki Tayama, and Yoshihiro Fukumoto. 2022. "Use of Anti-Thrombotic Drugs and In-Hospital Mortality in Acute Aortic Dissection Patients" Diagnostics 12, no. 10: 2322. https://doi.org/10.3390/diagnostics12102322
APA StyleHori, K., Morikawa, N., Tayama, E., & Fukumoto, Y. (2022). Use of Anti-Thrombotic Drugs and In-Hospital Mortality in Acute Aortic Dissection Patients. Diagnostics, 12(10), 2322. https://doi.org/10.3390/diagnostics12102322
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
